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Abstract
THE ECONOMIC IMPACT OF ANTIMICROBIAL RESISTANCE IN PATIENTS
WITH NOSOCOMIAL STAPHYLOCOCCUS AUREUS BACTEREMIA
By Suzanne Toussaint Phillips
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2009
Major Directors: Ron E. Polk, Pharm.D. & Spencer E. Harpe, Pharm.D., M.P.H., Ph.D.

Background: The proportion of nosocomial Staphylococcus infections caused by
methicillin-resistant Staphylococcus aureus (MRSA) has increased from 22% in 1995 to
63% in 2004. Blood stream infections, more commonly referred to as bacteremias,
represented the majority (75.5%) of hospital-onset MRSA cases. The economic impact of
Staphylococcus aureus bacteremia merits investigation.

xi

Methods: This was a retrospective cohort analysis within Cerner HealthFacts data
warehouse. Eligible patients were those who had Staphylococcus aureus bacteremia and
were discharged between January 1, 2000, and December 31, 2006.

Inclusion criteria

include age > 18 years old and onset of infection > 48 hours post admission. The crude
association was measured by subtracting the total mean hospital charge for MSSA
bacteremia from the MRSA charge. A generalized linear model using a gamma
distribution and log link were used to determine the adjusted hospital charge and postinfection length of stay for the MRSA and MSSA groups. Path analysis was used to
describe the relationships between infection susceptibility status, LOS and total hospital
charge.

Results: During the study period, 930 patients meet all the inclusion and exclusion
criteria. The overall total hospital charge was $111,636 (MRSA = $121,713, MSSA =
$97,307.) The crude difference in mean charge was $24,406. The multivariable model
included predicted a MRSA patient would have an increased total charge of $22,889.
MRSA had a higher total charge but when patients were more severely ill, MRSA
charges decreased while MSSA charges increased. The second multivariable model
predicted a MRSA patient would have an increased post-infection LOS of 1.3 days.
However, the magnitude of increased post-infection LOS based on pre-infection LOS
was different for MRSA and MSSA patients. The path analysis model indicated the
direct and indirect effects of susceptibility status on both post-infection LOS and total
charge were relatively small.
xii

Conclusion: This investigation was the first large multi-center investigation to examine
the economic impact of MRSA and MSSA bacteremia. MRSA was associated with a
higher total charge and longer post-infection LOS than MSSA patients. The path analysis
model analyzed suggests the actually role of infection susceptibility status on postinfection LOS and total charge was minor.

xiii

CHAPTER 1
Introduction

Overview of the document
This dissertation describes a study designed to examine the relationship between
Staphylococcus aureus bacteremia susceptibility status (methicillin resistant or
susceptible) and hospital charges. This chapter provides background information
necessary to understand the significance of the project. The second chapter
systematically reviews the available literature and provides more extensive background
on previous investigations, economic issues, confounding factors, propensity scores and
path analysis. Chapter 3 discusses the preliminary investigation. Chapter 4 describes the
methodology used for the dissertation project. The results are provided in Chapter 5,
followed by a discussion and concluding remarks in Chapter 6.

1

Background
Ever since the discovery of antibiotics, resistance has been emerging.
Antimicrobial resistance is an important public health issue. In 1999, the Centers for
Disease Control and Prevention (CDC) and several other national agencies developed an
Interagency Task Force dedicated to antimicrobial resistance. Each year since its
inception, the Antimicrobial Task Force has published an Annual Report describing the
current state of resistance in the US.[1] According to the CDC, the proportion of total
nosocomial Staphylococcus species infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) has increased from 22% in 1995 to 63% in 2004. [2]
Additionally, a recent investigation sought to describe the incidence and distribution of
invasive MRSA in nine communities across the United States.[3] The results showed
blood stream infections, more commonly referred to as bacteremias, represented the
majority of hospital-onset MRSA cases (75.5%).
The scientific community and healthcare professionals have acknowledged the
importance of understanding the economic impact of resistance. The “cost of resistance”
has been defined as “the incremental cost of care for an infection due to a resistant isolate
minus the care costs of infection with a susceptible strain of the same organism.”[4] For
this analysis, the “cost of resistance” can be approximated by subtracting the total
hospital charges of the susceptible from the resistant groups. The difference in charges
estimates the “cost of resistance.”
Performing and/or interpreting an economic analysis requires further explanation.
For example, the terms costs and charges must be defined. Some authors have used the
2

terms interchangeably, but this is incorrect. Costs and charges reflect different economic
values. Specifically, charges always over-inflate cost. [5] For the purposes of this report,
great care has been given to use the terms costs and charges appropriately. Previous
investigations have used costs or charges as outcomes depending on study design and
data availability. The economic background section provides a more thorough discussion
of costs versus charges.
Any epidemiologic investigation attempting to describe the relationship between
an exposure and outcome must consider potential confounders. Confounding factors are
variables that (1) are associated with the outcome as well as the exposure, and (2) are not
variables in the causal pathway. If confounding exists, an association may appear to be
present when one does not exist or there may seem to be no association when a true
association does exist.[6] Therefore, it is imperative to identify confounders and control
for them. In most situations confounders are identified a priori based on previous
investigations or expert knowledge.[7] For this investigation, underlying severity of
illness and comorbid conditions were identified as confounders. [8] Additionally,
hospital level factors (e.g. teaching status, bed size, geographic location) can also
confound the relationship between susceptibility status and total charges.
Propensity scores are another way to control for confounding. Observational
studies employ this method to eliminate bias from an unequal distribution of confounders
thereby mimicking the purpose of randomization in a randomized, controlled clinical
trial. Propensity scores are the probability of exposure given measured baseline
variables.[9] This probability can then be used as a matching or stratification factor, as a
3

covariate in multivariable model or to perform inverse probability of exposure
weighting.[10]
The relationship between susceptibility status and charge is further complicated
by length of stay (LOS). LOS must be considered in two parts as it relates to the onset of
a nosocomial infection. The pre-infection LOS refers to the number of days in the
hospital before infection onset. The post-infection LOS refers to hospital stay after the
infection onset. Post-infection LOS is an intermediary between susceptibility status and
charges. Pre-infection LOS is related to infection susceptibility, post-infection LOS and
total charge. Therefore, pre-infection LOS can be considered as confounding the
relationship between infection susceptibility status and charges. A technique called path
analysis can be used to provide estimates of the magnitude and significance of
hypothesized relationships between variables when some of the variables lie in the
proposed causal pathway.
Previously, single center investigations have suggested that MRSA bacteremia
may increase hospitalization costs by 1.2- to 2-fold over methicillin-susceptible
Staphylococcus aureus (MSSA) bacteremia.[11-15] This supports the hypothesis that
MRSA bacteremia is associated with higher costs than MSSA bacteremia. However, one
study performed in three German hospitals indicated that hospital costs between patients
with MRSA and MSSA patients with blood stream infections were similar.[16] A large
multi-center investigation may help to quantify the economic impact of MRSA vs. MSSA
bacteremia.

4

Objectives
The current investigation has four primary objectives which are listed below.

1. Measure the crude difference in total hospital charges between methicillin-resistant
Staphylococcus aureus (MRSA) vs. methicillin-susceptible Staphylococcus aureus
(MSSA) bacteremia.

2. Determine the impact of methicillin resistance vs. methicillin susceptibility in
Staphylococcus aureus bacteremia (SAB) on total hospital charges while adjusting for
potential confounders.

3. Determine the impact of methicillin resistance vs. methicillin susceptibility in SAB on
post-infection length of stay (LOS) while adjusting for potential confounders.

4. Describe the relationships between SAB methicillin susceptibility, LOS and total
hospital charges.

Significance
As described above, the incidence of MRSA is increasing and the majority of
hospital acquired MRSA infections are bacteremias.[3] These factors stimulate the need
for further investigation into the relationship between MRSA and MSSA bacteremia.
5

Before a clinician prescribes a drug, the potential risks and benefits must be
considered. The benefit of prescribing an antibiotic often outweighs the adverse
consequences for an individual patient since the side effect profile of most antibiotics is
reasonably mild. However, with each antibiotic administration antimicrobial resistance is
a potential unintended consequence. By identifying any unintended financial
consequences, strategies for minimizing the costs and thereby resistance can be more
fervently pursued. For example, infection control strategies are expensive but they may
seem more manageable if the “cost of resistance” is significantly more. Finding ways to
minimize resistance through an economic approach will positively impact public health.
The scientific community and healthcare professionals recognize the importance
of understanding the economic impact of resistance.[4] Understanding the financial
implications associated with MRSA will better equip hospitals to manage their financial
resources.
Also, the relationship between infection susceptibility status with respect to LOS
and total hospital charges needs to be more appropriately defined. It is common
knowledge that LOS greatly contributes to hospital charges. But the relationship between
pre- and post-infection LOS, infection susceptibility status and charges has not been fully
characterized. Previous investigations have explored charges/costs and LOS as
independent outcomes. Path analysis will be used to characterize the relationship
between infection susceptibility status, LOS and total charge.
Data from over forty hospitals will be considered making this a large multi-center
investigation. This includes both academic teaching medical centers and community
6

hospitals. Previous investigations only explored the economic impact of SAB in teaching
hospitals. A multi-center investigation will provide a larger sample size than previous
single center reports. This investigation will have greater external validity than previous
studies.

7

CHAPTER 2
Literature Review

MRSA Bacteremia Overview
Staphylococcus aureus is a significant cause of infectious disease in humans.
More specifically, it is an important cause of bloodstream infections. MRSA accounts for
more than half of all S. aureus infections in many institutions. MRSA rates have been
reported as high as 70% in Intensive Care Units (ICUs).[17] These are serious infections
with mortality rates ranging from 15 to 60%.[13, 14, 18-22] MSSA infections can also
be fatal. A meta-analysis estimated the mortality rate of MSSA bacteremia to be
12%.[23]
Why do some patients have MRSA versus MSSA infections? The investigators at
the Mayo Clinic list 4 risk factors for an MRSA infection (1) a current or recent
hospitalization, (2) residing in a long term care facility, (3) invasive devices, and (4)
recent antibiotic use with fluoroquinolones (ciprofloxacin, ofloxacin or levofloxacin) or
8

cephalosporins.[24] Published reports have expounded on these 4 risk factors by
subdividing the categories into areas of greater risk. For example, in an investigation
published by McHugh et al.[13], factors including cardiac surgery during hospitalization
and venous or bladder catheter > 3 days during hospitalization were identified to increase
the risk of MRSA over MSSA. However, both infections caused by MSSA or MRSA are
a serious public health concern meriting additional attention.

Economic Analysis of MRSA Bacteremia Overview
Several authors have identified key factors to consider when estimating the cost of
resistance. Within the context of these publications, the considerations discussed were
within a theoretical framework. Each author discussed how an investigation into the
“cost of resistance” should be designed. A compilation of these considerations is
summarized below in Table 2.1. McGowan was the first to distinguish the various
viewpoints which determine applicable costs.[25] Such perspectives include the
physician, the patient, the healthcare business, the drug industry and society. Ultimately,
the societal/public health perspective would reflect the most comprehensive economic
impact of resistance. This viewpoint would consider resistance from the perspective of
the social good. Defining the economic burden of resistance quickly becomes
complicated when forced to consider the long-term implications of antimicrobial usage.
For example, treating a patient’s infection with an antibiotic may expedite that patient’s
recovery, which would decrease short-term expenses. But antibiotic usage indirectly
increases resistance thus increasing the overall cost of resistance to society despite the
9

individual patient’s short-term savings. It is less complicated to define the economic
burden of resistance from the hospital perspective. This perspective only considers
expenditures that directly impact the hospital. Defining the perspective is an essential
first step in any economic analysis as it determines what “costs” will be considered. [26]
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Table 2.1 Key factors to consider in estimating the cost of resistance
Cosgrove
&
Carmeli
[27]

Howard
et al [4]

McGowan
[25]

Patient Characteristics
Severity of underlying illness
X
Mortality
X
X
Morbidity
X
Length of stay (LOS)
X
X
Intensive care unit (ICU) admission
X
Need for surgery/other procedures
X
Status at discharge (functional)
X
X
Economic Considerations
Hospital cost (fixed and marginal)
X
Per day per bed by specialty
X
Per day per bed ICU vs. general vs. other
X
Antimicrobial acquisition costs
X
Antimicrobial administration costs
X
Staff time increase (MD / nurse)
X
Occurrence of other procedures
X
Occurrence of other infections/complications
X
Lab costs (screening and diagnosis)
X
Infection control staff
X
Treatment failure
Hospital charges (larger than costs)
X
Resources utilized
X
Supplies, housekeeping, waste disposal, etc.
X
Hospital Factors
Infection Control Practices
Formularies/Protocols
Educational Programs
The “x” represents factors identified in each paper as important considerations.
LOS = length of stay
ICU = intensive care unit
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X

X
X
X
X
X
X
X

The choice of control group was very important. One of the pioneer studies
examining SAB compared resistant infections to both susceptible patients and to patients
without blood stream infections.[14] Although uninfected hospitalized patients represent
the true source population, this comparison assesses the burden of having a resistant
infection rather than no infection. Comparing a resistant to a susceptible infection is
appropriate when trying to determine the excess economic burden attributable to the
resistant infection.[27] The rest of the investigations discussed used a susceptible control
group.

Economic Background
Understanding costs, charges and reimbursements from a hospital’s perspective is
complex. In a strictly economic sense, a cost can be thought of as “the extra amount of
resource consumption incurred for providing a service as compared to the costs of not
providing that service.” [5] In layman’s terms, costs refer to the price a hospital pays for
the resources it consumes. This is different than a charge, which is simply a list price that
hospitals charge to their customers. [5] Charges are always higher than the actual
hospital cost so that patients who can pay will cover the losses from those who cannot
afford to pay. [5]
Hospital reimbursements are an entirely different level of complexity. The
government, through Medicare and Medicaid, is the major payer of hospital services in
the United States. In 1982, Medicare moved to a prospective payment system (PPS) for
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hospital reimbursement to control costs by capping the allowable reimbursement.[28] A
hospital’s listed charge, therefore, is not the same as the insurance reimbursement.
PPS works by dividing admissions into diagnosis-related group (DRG) categories.
A DRG is computed taking into account the affected organ system, up to nine ICD-9-CM
diagnosis codes, up to 6 ICD-9-CM procedure codes, morbidity and gender. Each DRG
has an associated DRG relative weight. DRG relative weights reflect the average level of
resources a Medicare patient in a particular DRG will utilize. The weight can range from
greater than 0 to less than 20. An average hospital stay would have weight of 1.
Conditions with greater costs are assigned a higher DRG relative weight. Hospitals are
then reimbursed a fixed rate depending on the relative weight of the DRG.
Reimbursements are also adjusted for geographic differences in wage, hospital teaching
status, proportion of low income individuals a hospital treats and cost outliers.[29]
Since charges are known to inflate the economic burden of hospitalization, costto-charge ratios have been used to better approximate actual cost from charges [11];
however, cost-to-charge ratios are a poor approximation of actual costs.[30] Additionally,
cost-to-charge ratios are specific for a particular hospital. The identity of a hospital must
be known to determine which cost-to-charge ratio is appropriate. Cost-to-charge ratios
were not used in this analysis since the identity of each hospital was unknown.
As previously mentioned, hospital charges are considered to be a gross
overestimation of the true hospitalization cost. But the difference between MRSA and
MSSA bacteremia for charge and cost has been shown to be similar.[31] Although this
observation has been noted in the literature, mathematics would suggest that a 50%
13

overestimation in charge would correspond to a 50% overestimation in the difference
between charges. Therefore, it will be more useful to discuss differences as percent
increase or relative change.
Descriptive statistics for variables that are non-normally distributed are
conventionally expressed as median and interquartile range. Charges/costs are rarely
normally distributed. It would seem logical to express the central tendency of charge/cost
as a median, but averages are used since economists are interested solely in means.[32]
This convention stemmed from the practical need to obtain annual budget data which
could be obtained by multiplying the arithmetic mean (average) by the total number of
patients. Therefore, means are the central tendency measures reported for charge/cost
data.[33]

Confounding Factors
Confounding factors are variables that are associated with the outcome as well as
the exposure. However, they cannot be variables in the causal pathway (i.e.,
intermediary) between the exposure and outcome. A directed acyclic graph (or a causal
diagram) depicting the relationship between exposure, outcome and confounder can be
found below in Figure 2.1.

14

Figure 2.1. Mechanism of confounding
Confounder

Exposure

Outcome

If confounding exists, an association may appear to be present when one does not
exist or there may seem to be no association when a true association does exist.[6] This
is because the confounder distorts the effect of exposure on outcome. It is important to
identify and control for confounding since it can lead to a misinterpretation of study
results.
Confounders should be identified from the base population, not the study sample.
This means that confounders are identified a priori based on previous investigations or
expert knowledge.[7] Since almost all investigations examine a small subset of a larger
population, it is possible that a confounding effect within the population may not be
present within the sample. Known confounders should be included regardless of their
“statistical significance” in the sample.
Once confounders are identified they must be controlled. This can be done during
the design phase through restriction, matching or randomization or during analysis via
stratification-, or multivariable analysis.[34] By definition, randomization should
equalize the distribution of all known and unknown confounders between the groups.
15

The technique is frequently used in prospective, experimental study designs. However,
the retrospective nature of database projects does not allow for this technique.
Retrospective investigations more commonly use restriction or matching. Restriction
involves limiting the scope of design to one stratum of the confounder but, this limits the
investigation’s external validity. Matching is used to make the groups comparable with
respect to the confounder. This technique requires more complicated analysis since the
matched nature of the data must be taken into consideration. Additionally, “overmatching” can become a concern if the groups become too similar as to disguise as actual
effect.[35]
As stated above, confounding can be controlled for at the analysis level through
stratification or multivariable analysis. When confounding exists, the magnitude of effect
will be the same between the strata but the crude estimate of effect of the exposure and
outcome will be different.[36] Stratification quantifies the relationship between exposure
and outcome as a pooled estimate with respect to the confounder. Stratification becomes
more complicated when multiple confounders exist because the statistical power to detect
a difference decreases as the number of observations within a stratum decreases.
Mathematical modeling during the analysis can account for many confounders
simultaneously. Randomization, restriction, matching, stratification, and multivariable
analysis are all methods for reducing confounding. Except for randomization, each
technique requires the confounder to be identified and cannot control any unmeasured
confounding effects.[37]

16

Several variables have been acknowledged as known confounders in the literature
regarding the relationship between infection susceptibility and charge. Specifically,
underlying severity of illness and comorbid conditions have been identified.[38]
Underlying severity of illness and comorbid conditions are both gauges of baseline health
status not actual disease acuity. There is an important distinction between underlying
severity of illness and severity of illness during the infection. Severity of illness during
the infection is considered an intermediary, not a confounder since a sicker patient would
require a longer length of stay and would increase total charges.
There is currently no universally recognized severity of illness score for infectious
disease outcomes.[27] Recently, a comorbidity risk-adjustment measure was developed
for MRSA infections.[39] The Chronic Disease Score (CDS) was modified to include
more co-morbidities to create a CDS-MRSA. Similar to the original CDS, patient
medications were used to identify the co-morbidities. This method has not yet been well
validated and it requires a complete medication history. Confounding attributable to comorbid conditions has been most commonly estimated using the Acute Physiology and
Chronic Health Evaluation (APACHE) score [40, 41], McCabe/Jackson score [42] and
the Charlson Comorbidity score.[43] The APACHE score is intended for use with ICU
patients and requires clinical parameters not generally available in administrative
databases.[40, 41] The McCabe/Jackson score has been evaluated for non-ICU patients
and has been used for patients with gram-negative infections. MRSA is a gram- positive
organism.[42] The Charlson Comorbidity Index was designed to measure the 1-year
mortality risk in a general population of hospitalized patients.[43] It has been modified
17

to use multiple International Classification of Disease, Ninth Revision, Clinical
Modification (ICD-9-CM) diagnosis codes to determine the score.[44] DRG categories
have also been used as a surrogate for severity of illness.[45] Although not well
validated, DRGs have been used as a surrogate for severity of underlying illness in
MRSA bacteremia.[13] DRGs were originally developed to accurately assess the cost of
hospitalization by accounting for severity of illness relative to other DRG classifications.
[46, 47] A more complete discussion of DRGs can be found in the economic background
section.
Data from a meta-analysis demonstrated a significant increase in mortality
associated with MRSA bacteremia relative to MSSA bacteremia.[20] Mortality is most
typically reported as discharged alive or expired. Differences in mortality are especially
important in an economic analysis since patients who die during their hospitalization
have truncated costs.
Length of stay (LOS) is known to increase hospital charges; however, LOS must
be considered in 2 parts as it relates to the onset of a nosocomial infection. The preinfection LOS refers to the number of hospital days before infection onset. The postinfection LOS refers to days after the infection onset. The relationship between infection
susceptibility status and total hospital charges is complicated by LOS. Post-infection
LOS is an intermediary between susceptibility status and charges. As discussed above, it
should not be included as a confounder in a model measuring the association between
total susceptibility and charges. Pre-infection LOS is related to infection susceptibility,
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post-infection LOS and total charges. Therefore, pre-infection LOS can be considered as
confounding the relationship between infection susceptibility status and charge.
Hospital level factors can also confound the relationship between susceptibility
status and total charges. As previously mentioned, DRG payments are calculated by
adjusting for hospital specific factors. Income wage index, hospital teaching status, and
percentage of low income patients are also confounders to be considered. These factors
are confounders since they directly impact hospital charges and are related to
susceptibility status.

Previous Investigations
As previously mentioned, there have been prior investigations attempting to
quantify the economic burden of MRSA bacteremia. They suggest MRSA bacteremia
increases hospitalization costs by 1.2-to 2-fold over MSSA bacteremia.[11-15] Table 2.2
below outlines investigations that examined MRSA vs. MSSA bacteremia. Only one of
the investigations used hospital charge as an outcome variable.[11] This investigation
also reported costs as calculated using Medicare cost-to-charge ratios. The estimated
difference in median charge attributable to MRSA vs. MSSA was 1.36 fold greater (1.44
for median attributable cost). Regarding the different estimates in hospitalization costs
between investigations, it has been hypothesized that the differences are due to disparities
in study populations and differences in calculating costs.[27] With the exception of one
investigation [16], all previous reports support the hypothesis that infections caused by
MRSA are associated with higher costs compared to MSSA infections.
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Table 2.2. Investigations comparing the economic impact of MRSA vs. MSSA bacteremia
Author

Setting

Sample Size

Data Source

Economic
variable

Abramson
MA., et al.
[14]

University
tertiary
care
center

8 MRSA
11 MSSA
19 Controls

Pairwisematched case
control study

Total & variable
direct costs of
hospitalization

• LOS
• Cost

Cosgrove,
S.E., et al.
[11]

University
tertiary
care
center

348
(96=MRSA)

Cohort study

Hospital
charges were
used to
approximate
costs using the
Medicare costto-charge ratio

• LOS
• Hospital
charges

Greiner
W, et al.
[16]

3
University
teaching
centers in
Germany

109

Retrospective
cohort study

Hospital costs
attributable to
bacteremia and
costs of other
bacteremia
related medical
services after
discharge.

• Mortality
• Cost

ESRD on
hemodialy
sis

Outcome
Measures

Result

Notes

• Attributable median
LOS: 12 vs. 4 days
(MRSA vs. MSSA)
• Attributable median
total costs: $27,083 vs.
$9,661 (MRSA vs.
MSSA)
• MRSA had a median
attributable LOS of 2
days
• MRSA had a median
attributable hospital
charge of $6,916
($3,836 median
attributable hospital
cost)
• No difference in
duration of stay,
outcome or mortality
between the groups.

MRSA and MSA
groups
compared to
non-infected
controls, not
each other.
Charges
reported were
post-infection
only.

Investigation
examined
communityacquired and
nosocomial
infections
separately.
Largest
component of
total costs was
the initial
hospitalization
(93%).

(continued)
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Table 2.2 (continued)
Author

Setting

Sample Size

Data Source

Lodise,
T.P., et
al.
[12]

University
tertiary care
center

353 (174
hospital
onset)

Retrospectiv
e cohort
study

McHugh,
C.G., et
al.
[13]

Tertiary-care
hospital

60
(20=MRSA,
42=MSSA)

Retrospectiv
e casecontrol study

Reed
SD., et
al.
[15]

105 hospital
patients

143
(54=MRSA,
89=MSSA)

Prospective
cohort study

ESRD on
hemodialysis

Economic
variable
Microcosting
structure:
fixed indirect
costs,
variable
direct costs,
& fixed
direct costs

Outcome
Measures
• LOS
• Costs

All hospital
costs
accrued by
the patient
during
hospitalizati
on
Hospital
costs for
index
hospitalizati
on and for
rehospitaliza
tion

• Cost

• Cost per day for MRSA
($5,878) vs. for MSSA
($2,073)

• Cost
• Costs at
12 wks

• Initial hospitalization
costs: $21,251 vs.
$13,978 (MRSA vs.
MSSA)
• 12 week costs: $25,518
vs. $17,354 (MRSA vs.
MSSA)

MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus
LOS = length of stay
ESRD = end stage renal disease
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Result

Notes

• Adjusted mean LOS:
19.1 vs. 14.2 days
(MRSA vs. MSSA)
• Adjusted mean hospital
cost: $21,577 vs.
$11,688 (MRSA vs.
MSSA)

Included both
hospital and
community
onset SAB.
Adjusted model
did include a
variable for
hospitalacquired SAB.
Used CMI for
severity of
illness.

Used
propensity
scores in
multivariable
regression.

There have been several single center investigations that have quantified the costs
of MSSA-SAB and MRSA-SAB.[11-15, 31, 48-52] Each report is briefly summarized
below. The first two investigation presented [11, 12] are the most similar to the current
study.
Cosgrove et al. [11] examined mortality, length of stay and hospital charges as
outcome variables using a cohort design. They concluded that median attributable
hospital charge for infection caused by MRSA bloodstream infections was $6,916 per
patient. Costs were also estimated using hospital charges adjusted by the Medicare costto-charge ratio from onset of infection until discharge. There was no significant
difference in mortality between the resistant and susceptible groups, but there was an
increased median attributable length of stay for MRSA of two days. This analysis did not
match patients with MRSA and MSSA bacteremia. Potential confounders were
controlled during statistical analysis. A multivariable model was constructed that
adjusted for whether a patient was receiving dialysis, involvement of prosthetic material,
comorbidities, surgical wound source, bone and joint source and a severity of illness
score.
Lodise et al. [12] characterized hospital costs in a retrospective cohort
investigation. Patients with infection caused by MRSA and MSSA were not matched,
rather baseline characteristics (e.g., hospital stay before infection onset, APACHE II, age,
source of bacteremia) were considered during statistical analysis. The total costs of an
infection caused by MRSA and MSSA was $21,577 and $11,668, respectively. All cost
data were log-transformed. The cost information reported was the actual cost according
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to the hospital where the investigation took place, the Detroit Receiving Hospital. A 1.4fold (4.9 days) longer post-infection LOS was observed in MRSA patients. This
investigation was limited to ICU patients.
Greiner et al. [16] evaluated the costs of nosocomial MRSA versus MSSA
bacteremia in patients undergoing hemodialysis. This retrospective analysis considered
patients who were hospitalized in one of three German centers. A German refined DRG
system was used to calculate costs which were reported in Euros. This investigation is
especially important since it found no difference in MRSA vs. MSSA costs and it
included data for three hospitals. However, there were only 49 patients between the three
hospitals. This investigation was limited to patients with end stage renal disease.
McHugh et al.[13] performed a case-control study to identify risk factors for
developing MRSA bacteremia. They did not initially match patients according to
severity of illness. However, patients were stratified into two groups based on their casemix index (CMI). CMI is a hospital level average of individual patient DRGs.
Therefore, CMI was used as a surrogate for severity of illness. They determined that the
cost of MRSA bloodstream infection was higher by nearly 120% as compared to MSSA
bloodstream infections when severity of illness was controlled. Cost data appear to
reflect costs from the entire hospitalization, not just the costs from infection onset to
discharge. Similar to the report by Lodise et al. [12] cost information appears to be
institution specific.
Abramson et al.[14] performed a pairwise-matched nested case-control study to
examine the impact of MSSA and MRSA blood stream infections on length of hospital
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stay, total costs and variable direct costs attributable to the infection. MRSA infections
had a higher median attributable cost than MSSA infections, $27,083 vs. $9,661
respectively. Costs were calculated using actual hospital costs (not charges) for the entire
hospitalization. The study matched MSSA and MRSA patients to non-infected hospital
controls. In a case-control design it is appropriate to match patients with an outcome
(MRSA or MSSA) to the entire at risk population (non-infected hospital controls). This
design does not allow for direct comparison between the MRSA and MSSA groups while
controlling for confounding.
Reed et al.[15] conducted a cost analysis of MRSA vs. MSSA bacteremia, but
their study was limited to patients receiving hemodialysis. This study compared initial
hospitalization costs and costs at 12 weeks after initial hospitalization. Initial
hospitalization costs were $21,251 vs. $13,978 for MRSA and MSSA respectively.
Twelve week costs were $25,518 vs. $17,354 for MRSA and MSSA respectively.
The following investigations are not included in Table 2.2 above. Their
methodology was not as similar to the current study. However, they will still be
discussed as relevant background information.
Kim et al. [50] performed an analysis to determine the economic burden of
MRSA in a university-affiliated, tertiary-care hospital. This analysis was not limited to
MRSA bacteremia, other infection sites included soft tissue, surgical sites, pneumonia
and osteomylitis. Additionally, patients were not matched. A chart review process was
used to determine the attributable days of hospitalization for each MRSA infection.
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Costs were then calculated for only attributable days of hospitalization. All costs were
reported in Canadian dollars.
Similar to Kim et al., investigations by Capitano et al. [51], Kopp et al. [31] and
Rubin et al. [52] were not limited to patients with SAB. Even though Kopp et al. [31]
did stratify based on infection location, cost information was not delineated based on
location. Also, patients were not matched according to severity of illness. Rubin et al.
[52] also stratified by type of infection, but did not match patients with MRSA to patients
with MSSA. An additional difference in the paper by Capitano et al. [51] was the longterm care facility setting. Data from long-term care facilities is not necessarily
generalizable to hospitals. However, all of these investigations reported higher
costs/charges for treating MRSA infections.
Chaix et al. [48] performed a cost-benefit analysis of an MRSA control program
in an ICU with endemic MRSA. They concluded that the mean cost attributable to
MRSA infection was $9,275. An unmatched case control study by Lepelletier et al.[49]
also examined ICU costs. The authors concluded that MRSA involved extra cost due to
antimicrobial treatment and quantified that cost in euros. Both of these French studies
have limited external validity due to their ICU focus.
The methodologies used in each of the above investigations have advantages and
limitations. The current study attempted to incorporate the strengths of these previous
investigations whenever possible.
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CHAPTER 3
Preliminary Study

Objectives

1. Estimate the crude hospital charges for treating methicillin-resistant Staphylococcus
aureus (MRSA) bacteremia.

2. Measure the association between MRSA bacteremia and total hospital charges.

3.

Estimate the adjusted hospital charges for treating MRSA bacteremia.

Methods
Study population
Eligible patients were those who had Staphylococcus aureus bacteremia (SAB)
and were discharged from the Virginia Commonwealth University Health System
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(VCUHS) between May 1, 2006, and April 31, 2007. If a patient had more than one
episode of SAB during their admission, only the first episode was considered.

Study Design
This was a retrospective cohort analysis within VCUHS. Data were extracted for
each patient from electronic medical records. The exposure of interest was infection
susceptibility, and the outcome was total hospital charges. Patients with Staphylococcus
aureus were assessed to be either resistant or susceptible to methicillin by the
microbiology laboratory at VCUHS. Susceptibility testing was performed and
interpreted according to the Clinical and Laboratory Standards Institute (formerly the
NCCLS) guidelines.[53] The dependent variable, total hospital charge, was obtained
from the hospital accounting department.

Data Collection
Data were collected from 2 databases within the hospital and integrated using
medical record numbers. First, the pathology database was electronically queried for
patients with Staphylococcus aureus bacteremia (SAB). Second, hospital accounting
provided charge information for each SAB patient.

Inclusion criteria
Patients were eligible for inclusion if they were > 18 years old and had a blood
culture obtained > 48 hours post admission. The onset of infection was defined as the
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time the blood culture was obtained. The length of stay from admission to onset had to
be at least 48 hours to infer hospital acquisition. Patients who were transferred from
another hospital, as noted by their admission source, were not required to be in the
hospital for > 48 hours for inclusion in the analysis.

Matching
Frequency matching on pre-infection LOS was used. This ensured the groups had
a similar duration of hospitalization before infection onset. The confounding effects of
pre-infection LOS on infection susceptibility and charge were controlled by matching.

Statistical Analysis
Descriptive statistics were reported as median and inter-quartile range (IQR) since
the outcome variable was not normally distributed. Proportions between the groups were
compared using Pearson’s chi-squared test. Continuous variables were compared using
the Wilcoxon Rank Sum test. A two-sided alpha of 0.05 was considered significant.
Statistical analysis was performed using JMP (version 7; SAS Institute, Cary, NC) and
SAS (version 9.1.3; SAS Institute, Cary, NC) software.
The median crude hospital charge was approximated from the data for the overall
sample and by infection susceptibility group. The median adjusted hospital charge was
calculated using a generalized linear model (GLM) with a gamma distribution and a log
link. This method employs maximum-likelihood estimation. The model’s predicted
values were used to estimate the median hospital charge by infection susceptibility group.
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The association between total hospital charge and infection susceptibility status
was measured by examining the infection susceptibility coefficient. Exponentiated
coefficients provide a ratio of means which can be re-expressed as the percentage
increase in mean cost per unit increase in the covariate.[54]
Before building the multivariable model, potential predictor variables were
assessed in univariate models. Variables had to have a p-value < 0.25 for consideration
in the multivariable model.
Since the association between susceptibility status and total hospital charge was
being examined, susceptibility status remained in the model without attention to
statistical significance. Homogeneity of slope was assessed by evaluating the interaction
terms between susceptibility status and each covariate. All one-way interactions were
assessed. The likelihood ratio test was used to determine if the interaction terms belonged
in the model.
Known confounders (i.e., DRG weight and discharge status) were included in the
model. Potential covariates not involved in effect modification were assessed for
confounding. A change of more than 10% in the coefficient for susceptibility status was
considered significant for confounding.
Influential diagnostics were performed to identify observations that could greatly
influence the multivariable model. The standardized Pearson residual and hii were used
to identify leverage, outlier and highly influential points. The affected coefficients were
identified using Cook’s D and DFBETAS. A correlation matrix was used to assess the
potential for pairwise multicollinearity.
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Results
During the study period, 219 episodes of SAB were identified. One hundred and
thirty-seven patients failed to meet the inclusion criteria. Of the remaining 82 patients,
72 patients met the frequency matching criterion (MRSA = 45, MSSA = 27). No MSSA
patients were excluded by the frequency distribution matching.
The overall median total hospital charge was $140,396. The charge for each
group can be found in Table 3.1. The crude difference in median charge was $80,771.

Table 3.1 Crude hospital charge in US dollars
Median
IQR
Minimum Maximum
Overall 140,396 63,236 to 308,847
11,896
1,169,816
MRSA 166,901 73,526 to 316,101
11,896
1,169,816
MSSA
86,130 52,675 to 232,370
32,498
761,555
IQR = interquartile range
MRSA = methicillin-resistant Staplylococcus aureus
MSSA = methicillin-susceptible Staplylococcus aureus

The median ages for the MRSA and MSSA groups were 55 years old and 53
years old, respectively. The MRSA group was 53.3% male while 51.8% of the MSSA
group was male. The susceptible and resistant groups appear balanced with respect to the
measured covariates.
The results of the univariate GLMs are available in Table 4. ICU status, age and
DRG weight were significant at p<0.25. Variables not significant in the univariate
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analysis were not considered for multivariable model inclusion, with the exception of
discharge status. Discharge status was included since it was a known confounder.
All two-way interaction effects between infection susceptibility status and the
four potential modifiers (ICU status, DRG weight, age and discharge status) were
assessed by including an interaction term for each in the multivariable model. Likelihood
ratio tests were used to compare the full and reduced models with different combinations
of the interaction terms. There were no significant interactions with infection
susceptibility status.
All possible two-way interactions between age, ICU status, DRG weight and
discharge status were assessed using likelihood ratio tests as described above. There
were two significant interactions; DRG weight and ICU status as well as ICU status and
age. These interactions were retained in the model along with the two associated lowerorder terms. No variables were assessed for confounding. All model variables were
either involved in effect modification or were known confounders.
The final model included organism (infection susceptibility status), DRG weight,
ICU, age, discharge status, an interaction between DRG weight and ICU and an
interaction between ICU and age. The parameter estimates were exponentiated for
interpretation (Table 3.2.)
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Table 3.2. Multivariable model exponentiated coefficients (hospital charge = dependent
variable)
Exponentiated Standard
Parameter
Coefficient
Error
Organism
1.276
1.16
DRG weight
1.455
1.11
ICU status
1.437
1.79
Age
0.985
1.01
Discharge status
0.845
1.22
Age x ICU status
1.026
1.01
DRG weight x ICU status
0.743
1.11
Organism = infection susceptibility (MRSA vs. MSSA)
DRG = diagnosis related group
ICU = intensive care unit

Wald 95% Confidence
Limits
0.95
1.71
1.18
1.79
0.46
4.47
0.97
1.00
0.57
1.25
1.01
1.05
0.60
0.94

No pairwise multicollinearity was found. There were no leverage points but six
observations were identified as outliers. The analysis was rerun without the outliers and
the parameter estimates were within the original model’s confidence intervals; thus,
removing the outliers did not alter the regression coefficients. Cook’s D identified seven
observations that may be affecting the regression coefficient estimates. The DFBETAS
for these observations indicated the regression coefficient most influenced was the scale
parameter.
The multivariable model predicted an overall charge of $163,811 (IQR $117,029
to $230,954). The MRSA and MSSA median charges are presented in Table 3.3.
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Table 3.3. Predicted charges
Overall
MRSA
Median ($)
163,811
186,559
IQR ($)
117,029 to 230,954 125,324 to 308,003
IQR = inter-qurtile range
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus

MSSA
145,345
101,440 to 187,123

According to the model, a case of MRSA bacteremia is expected to cost $41,214
more than a case of MSSA bacteremia. This represents a mean increase of 28% for
MRSA over MSSA bacteremias.

Discussion
According to the multivariable model, a case of MRSA bacteremia will have 28%
higher costs than an MSSA bacteremia. The 95% confidence interval for this estimate
ranges from 5% decrease to a 71% increase. Since the confidence interval included no
difference (i.e., 1), there is not a statistically different mean charge between the 2 groups.
The point estimate was, however, consistent with the 44% increase published in another
report.[55] Being discharged alive from the hospital (as opposed to expiring during
admission) is associated with a decrease in charge by 15%.
DRG weight, ICU status and age are all involved in effect modification and
therefore must be interpreted in light of that interaction. The impact of age while not in
the ICU would be a decrease in charge by 1.5% for each additional year of life. In the
ICU, each additional year increases charges by 1%. The impact of a one unit increase in
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DRG weight when not in the ICU would be an increase in charge of 46%. In the ICU,
each unit increase in DRG weight would only increase charges by 8%.
The literature has reported differences in charge as ranging from $5,000 to
$40,000 [11-14, 56-59] The crude difference in charge between MRSA and MSSA,
$80,771, was much greater than previously reported values. The adjusted difference in
charge, $41,214, was still slightly higher than values reported in other investigations.
This study found a 1.28-fold increase in charges associated with MRSA bacteremia as
compared to MSSA bacteremia. This is consistent with previous reports which report a
1.2-to 2-fold increase.[12, 13]
Previous methods for calculating the economic burden of resistance have varied
largely. Many single center investigations were able to collect actual cost from their
institution.[12, 14, 15] Another investigation was able to identify only costs associated
with the SAB.[16] And one of these investigations was able to collect costs attributable
to SAB after hospital discharge.[16] Charges were not able to be sub-categorized in this
analysis since only an overall aggregate charge was available for each subject.
Since charges are known to inflate the economic burden of hospitalization, costto-charge ratios have been used to better approximate actual cost from charges [11];
however, cost-to-charge ratios are a poor approximation of actual costs [30], which is
why they were not used in this investigations. Hospital charges are considered to be a
gross overestimation of the true hospitalization cost but, the difference between MRSA
and MSSA bacteremia for charge and cost has been shown to be similar.[31]
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As previously stated, adjusting for underlying severity of illness was a major
concern in this investigation. There is currently no well-validated illness severity score
for infectious disease outcomes.[27] Other investigations have used a variety of
techniques including APACHE score [12, 18], McCabe/Jackson score [11] and the
Charlson comorbidity score.[60] The APACHE score is intended for use with ICU
patients while the McCabe/Jackson score has been evaluated for non-ICU patients. The
calculation of the Charlson comorbidity score required parameters not available in this
analysis (i.e. multiple ICD-9-CM diagnosis codes). This lack of information precluded
the calculation of a Charlson comorbidity score. DRGs have been used as a surrogate for
severity of underlying illness in MRSA bacteremia.[13] This approach was originally
developed to accurately assess the cost of hospitalization by adjusting for severity of
illness within the DRG classification scheme.[46, 47] This investigation used DRG
weights to adjust for severity of underlying illness.
This analysis is based on two fundamental assumptions. First, the charges prior to
infection onset are comparable between the MRSA and MSSA groups. The VCUHS
billing department provided one charge for the entire hospitalization. Charges were not
available as pre- and post-infection charges. Differences in pre-infection charges could
bias the study results. Specifically, the difference in total hospital charge would be
overestimated if pre-infection charges were higher in the MRSA group. The difference
would be underestimated if the pre-infection charges were higher in the MSSA group.
Second, the charges are assumed to be a result of the resistant or susceptible bacteremia.
Hospital charges unrelated to the bacteremia introduce bias into the investigation and also
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inflate the difference in hospital charges between the MRSA and MSSA and overestimate
charge. There is no indication that either assumption was violated.
There were several additional limitations in this investigation. The study relied
on previously collected data. Retrospective data can be convenient since the researcher
does not have to wait for the data to be prospectively collected. However, records must
be complete and accurate or the results will be biased.[61] This dataset contained no
missing data.
The small sample size of this investigation limited its precision. This and all
previous investigations are plagued by their small sample size. The size of this
investigation was comparable to the size of previous reports. A multi-center
investigation is needed to adequately power an investigation to achieve accurate and
precise estimates.[4]
No attempt was made to estimate the charges associated with infection control. It
was assumed that any infection control measures would be the same for all patients
within the study timeframe since all patients were from the same hospital. It should be
noted that the incidence of MRSA infections can be reduced substantially through
prevention.[62]
Finally, the modeling technique used also greatly influenced the results. The use
of GLMs is not without limitations. The choice of link function and distribution can
greatly impact the model’s success. The distribution and link function were appropriately
defined prior to analysis; however, the exploration of different link functions and
distributions may have altered the parameter estimates. Although the impact of outliers is
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minimized, extreme charge values can still influence parameter estimates.[63] The
impact of outliers in this investigation is thought to be minimal since the removal of
outliers did not significantly change the parameter estimates. The last modeling
limitation could probably be more accurately referred to as investigator naivety. Many
unanticipated problems arose using the specified GLM. For example, many of the
influential diagnostics that are computed automatically for linear regression were not
available using PROC GENMOD in SAS. Fortunately the SAS Institute has published
some macros that compute some of these diagnostics, but adapting the macro to the study
data was less than intuitive.
The results of this investigation are similar in generalizability to the previous
investigations. The study was performed in a large tertiary care teaching hospital where
patient acuity is relatively high. These results may not extend to a community hospital.
To increase external validity, any future investigations should include a variety of
hospitals with differing characteristics.

Conclusion
The purpose of this investigation was to quantify the additional hospitalization
charge attributable to methicillin-resistant vs. methicillin-susceptible SAB. This
objective was achieved by estimating the crude hospital charge for treating MRSA and
MSSA bacteremia, measuring the association between MRSA bacteremia and total
hospital charges, and estimating the adjusted hospital charge for treating MRSA
bacteremia.
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The crude “cost of resistance” for treating MRSA bacteremia was estimated and
the association between MRSA bacteremia and total hospital charges was explored. The
crude difference in hospital charges was $80,771 and the adjusted difference was
$41,214. The model accounted for around half of the disparity in cost. The association
between bacteremia susceptibility status and hospital charges was a 1.28-fold increase for
resistant infections.
Future research in this area is still needed. A large, multi-center investigation
needs to be performed to more precisely estimate the association between MRSA/MSSA
bacteremia and hospital charges. Also, investigation is needed to explore the relationship
between susceptibility status, pre- and post-infection length of stay and hospital charges.
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CHAPTER 4
Methods

Data Source
Cerner HealthFacts (Cerner Corporation, Kansas City, MO) is a national data
warehouse that represents the electronic patient charts from millions of inpatient
admissions and emergency department and outpatient visits at U.S. healthcare
organizations.[64]
Within Cerner HealthFacts, patient records (UB-92/UB-04 standard format)
contain detailed information on inpatient care. This includes: principle and secondary
diagnosis codes (in International Classification of Diseases, 9th Revision, Clinical
Modification [ICD-9-CM] format), inpatient procedure codes (in ICD-9-CM format),
patient demographic information (age, insurer and gender) and hospital demographic
information (teaching status and urban/rural). The database also contains admission and
discharge dates as well as time stamped microbiologic susceptibility to methicillin for
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bacteremia. The analysis was conducted from a hospital perspective. Therefore, only
data elements which were important from a hospital perspective were considered.
DRG relative weights from 2006 were used as listed by the Centers for Medicare
and Medicaid Services (CMS) in the Acute Inpatient files for download.[65] The
weights were integrated into the project database. As previously discussed, each DRG
code was assigned a relative weight. DRG weights from 2006 were used since all
charges were adjusted to their 2006 value. These relative weights are publically available
through CMS.

Study population
The data warehouse was electronically queried for patients with Staphylococcus
aureus bacteremia (SAB). Eligible patients were those who had SAB and were
discharged by a hospital whose data were collected by the Cerner HealthFacts between
January 1, 2000, and December 31, 2006. So that every observation within a hospital
was independent, only the first episode of SAB per patient was considered.

Inclusion and Exclusion Criteria
Inclusion criteria include: age > 18 years old and onset of infection > 48 hours
post admission. The length of stay from admission to onset must have been at least 48
hours to infer hospital acquisition. Patients who were transferred from another hospital
as their admission source were excluded.
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Study Design
This was a retrospective cohort analysis using the Cerner HealthFacts data
warehouse. The exposure of interest was infection susceptibility, and the outcomes were
post-infection LOS and total hospital charges. Patients were identified as having SAB
according to microbiologic susceptibility determined by the hospital’s microbiologic
laboratory. Infection susceptibility standards were developed by the Clinical and
Laboratory Standards Institute (formerly the NCCLS) guidelines[53].

Matching
Frequency matching is a technique that can be used to achieve reasonable
efficiency between two groups. This investigation used frequency matching by preinfection LOS to exclude observations with an extremely long pre-infection LOS. The
MRSA and MSSA groups should have similar hospital lengths of stays before infection
onset. However, the confounding effects of pre-infection LOS on infection susceptibility
and charge cannot be completely controlled by frequency matching. Therefore, preinfection LOS was also used as a variable in the multivariable model.[66]

Outcomes
There were two outcomes of interest in this analysis. First, post-infection LOS in
days was evaluated. For the purposes of this analysis, LOS was divided into two parts.
The pre-infection LOS is the LOS from admission to the time when the initial positive
blood culture was drawn. For this analysis, the time of blood culture is referred to as the
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infection onset. The post-infection LOS is the LOS from infection onset to discharge.
This distinction attempted to designate the hospital stay attributed to the SAB from the
stay attributed to the primary reason for hospitalization.
Second, total charges in US dollars were assessed. Charges were adjusted for
inflation using the 2006 Consumer Price Index for hospitals.[67] When comparing
economic values over multiple years the relative value of money must be considered.
Normally, money is worth less in the future than it is worth today. Therefore, past dollars
must be adjusted for inflation.[68]
The consumer price index (CPI) measures the average change over time of goods
and services and is generally used as a measure of inflation. The reference index for the
CPI is set at 100 which represents the average price level for the 36 month period
between 1982 and 1984. The reported annual CPI reports a change relative to the
reference index. For example, an index of 120 would mean that there has been a 20%
increase in price since the reference period. An index less than 100 would reflect a
decrease in price. Movements of the index from one date to another can be expressed as
the difference between index levels. But, it is more useful to express the movements as
percent changes. The CPI allows for comparisons of consumer costs over time. Table
4.1 below shows the CPI of medical care services that pertain to hospital and related
services.
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Table 4.1. Consumer Price Indexes for Hospital and Related Services: 2000 to 2006
CPI for Hospital and Related
Services
2000
317.3
2001
338.3
2002
367.8
2003
394.8
2004
417.9
2005
439.9
2006
468.1
CPI = Consumer Price Index

Percent change from previous
year
6.62
8.72
7.34
5.85
5.26
6.41

Statistical Analysis by Objective
Statistical analysis was performed using JMP (version 7; SAS Institute, Cary, NC)
and SAS (version 9.1.3; SAS Institute, Cary, NC) software. JMP was primarily used for
descriptive statistics while SAS was used for the GLM and path analysis. Proportions
between the groups were compared using Pearson’s chi-square. Continuous variables
were compared using a Wilcoxon Rank Sum test. A two-sided alpha of 0.05 was
considered significant. The following statistical methods were used to address each
objective.
Modeling economic data is less than straightforward. The most commonly used
regression technique, ordinary least squares (OLS), is not generally appropriate for the
following reasons.[69] First, the dependent variable, total hospital charge, is rarely
normally distributed. The typical distribution is bounded by zero with a long right tail
(most closely resembling a gamma distribution). OLS requires the error terms to be
normally distributed for statistical inference. The second problem with OLS is the
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homogeneous variance assumption. With economic data the variance often increases as
the mean increases making OLS inappropriate. Several statistical solutions have been
proposed to more appropriately model charges.
A log transformation can be performed to make the dependent variable more
normally distributed. However, resulting estimates are in terms of “log charges.” This
often leads to problems with interpretation. Smearing factors have been used to
transform economic data from logarithmic back to natural units, but these factors can
introduce substantial bias in the presence of heteroscedasticity.[70]
A generalized linear model (GLM) can be used to create virtually any model. The
most appropriate distributions for cost data would be the gamma or inverse Gaussian
distribution.[71] Both of these distributions are appropriate for non-zero continuous
outcomes. However, most economic data analysis utilizes the gamma distribution.[54]
The gamma distribution is also appropriate since it assumes that variance is proportional
to the square of the mean. Economic data is non-zero, continuous and usually has a
variance which increases with the mean. The negative binomial distribution would not be
appropriate since it assumes a categorical outcome. The link function is not a
transformation on the data, but a transformation of the population mean. The most
commonly used link function for economic analysis is the log link.[54] Although the log
link is not the canonical link function for the gamma distribution, it has been used to
analyze cost data because it will not predict a negative value. Using the log link, an
exponentiated coefficient provides a ratio of the means.[54]
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Observational investigations attempt to estimate the effect of an exposure by
comparing outcomes for subjects not randomly assigned to the exposure of interest.[72]
In randomized clinical trials, random assignment serves to balance covariates so that the
study groups are comparable with respect to the distribution of their covariates.[73] The
presence of dissimilar groups can introduce systematic error into an observational
study.[61]
The theory of counterfactuals contemplates the outcome of the exposed group if
there was no exposure or conversely the outcome of the unexposed if there had been
exposure. The term “counterfactuals” indicates that at least one of the two circumstances
is contrary to fact.[6] There is no way to estimate the counterfactuals, but the bias of the
estimates can be corrected through the predicted probability of exposed vs. unexposed
using observed predictors. The predicted counterfactual can be estimated using
propensity scores.
Propensity scores are the probability of exposure given measured baseline
variables.[9] Observational studies employ this method to adjust for observable bias with
the goal being to eliminate bias from unequal distribution of confounders. To do this, a
group of likely confounders is converted into one scalar score through a two-stage
process. The actual propensity score is unknown and therefore must be estimated using a
logit or probit regression model where the dependent variable is exposure status and the
independent variables are the potential confounders.[74] The score is the probability (0 ≤
propensity score ≤ 1) of receiving the treatment (i.e., exposure) based on the set of
identified covariates as predicted by the first stage regression model. The score can be
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used as a matching or stratification factor, as a covariate in multivariable model or to
perform inverse probability of exposure weighting.[10]
Propensity scores can be used to match patients between exposure groups on
multiple confounders. However, the possibility of over-matching must be considered.
This occurs when matching is done incorrectly or unnecessarily. The more variables used
to calculate the propensity score, the greater the likelihood of overmatching. To avoid
overmatching, the propensity score should preferably include only established
confounders.[75]
As previously discussed, stratification becomes difficult when many confounders
are present since there are not enough observations in each stratum. Stratification on
propensity score limits the number of stratum thus making stratification a more robust
method to control for confounding.[76]
If the score is used in a multivariable model, the second part of the two-stage
regression process is the traditional model where the dependent variable is the outcome
of interest and the propensity score is used as a covariate. The advantage of including
propensity scores over traditional regression is in not over-parameterizing the model. [77]
Normally each confounder would require one degree of freedom (df) while the propensity
score, which could be comprised of many confounders, only requires 1 df.
Several papers have been published exploring propensity score methodology.[9,
74, 78] Of particular interest, an investigation examining the economic impact of MRSA
bacteremia used propensity scores.[15] The propensity score was calculated using
demographic characteristics, comorbidities, risk factors, clinical characteristics and
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infection related factors. It was then used as an independent variable in the multivariable
model. This investigation will be discussed more fully later in this report.
Propensity scores are not without limitation. They do not balance uncorrelated,
unmeasured characteristics and confounders.[79] Unmeasured confounding can be dealt
with using other methods. Additionally, covariates cannot be used that are directly
affected by the exposure of interest.[80] If the covariate is directly affected by the
exposure, it may be an intermediary not a confounder. Including an intermediary in the
propensity score would introduce bias into the investigation. Lastly, the models used to
generate the propensity score rely on the same assumptions as logistic regression. If the
model uses the propensity score as a continuous variable, the assumption of a (log-)
linear association with the dependent variable must be tested using categories. The
covariates must be balanced across the groups.[81]

Objective 1: Measure the crude difference between infection susceptibility status MRSA
vs. MSSA bacteremia and total hospital charges.
This aim was accomplished by subtracting the mean MSSA charge from the mean
MRSA charge. The charges were compared using a Wilcoxon Rank Sum test.
Additionally, trends in hospital charge over the study period were examined using
repeated measures analysis of variance (ANOVA). Tukey’s HSD was performed if a
significant difference was found.
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Objective 2: Determine the impact of methicillin resistance vs. methicillin susceptibility
in SAB on total hospital charges while adjusting for potential confounders.
The impact of infection type on hospital charge was calculated using a GLM with
a gamma distribution and a log link while adjusting for various factors. This method
employs maximum-likelihood estimation. Variables with a univariate p-value < 0.25
were eligible for inclusion in the multivariable model. Known confounders (e.g. severity
of illness, DRG weight) and potential covariates were eligible for inclusion. A
propensity score was used to include hospital level factors (e.g., hospital teaching status,
urban/rural status). Propensity scores require a two stage regression procedure. In the
first stage, the outcome variable was infection susceptibility and the independent
variables were the hospital level factors. The second stage was the multivariable model
where the predicted value from the first model was used as an independent variable. The
covariates were checked for balance. Using the predicted values from the multivariable
regression model, the mean charge of MSSA bacteremia was subtracted from the mean
charge of MRSA bacteremia.

Objective 3: Determine the impact of methicillin resistance vs. methicillin susceptibility
in SAB on post-infection LOS while adjusting for potential confounders.
The impact of infection type on post-infection LOS was calculated using a GLM
with a gamma distribution and a log link while adjusting for various factors. This method
employs maximum-likelihood estimation. Variables with a univariate p-value < 0.25
were eligible for inclusion in the multivariable model. Known confounders (e.g., severity
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of illness, DRG weight) and potential covariates were eligible for inclusion. A
propensity score was used to include hospital level factors (e.g., hospital teaching status,
urban/rural status). Propensity scores require a two stage regression procedure. In the
first stage, the outcome variable was infection susceptibility and the independent
variables were the hospital level factors. The second stage was the multivariable model
where the predicted value from the first model was used as an independent variable. The
covariates were checked for balance. Using the predicted values from the multivariable
regression model, the mean LOS of MSSA bacteremia was subtracted from the mean
LOS of MRSA bacteremia.

Objective 4: Describe the relationship between SAB methicillin susceptibility, LOS and
total hospital charges using path analysis.
Path Analysis is a type of analysis that uses multiple regression modeling to
explore complex relationships. The purpose is to provide estimates of the magnitude and
significance of hypothesized connections between variables. As previously discussed,
the relationship between hospital LOS and total hospital charges is not simple. Postinfection LOS is an intermediate between infection susceptibility and hospital charges.
Although pre-infection LOS confounds the relationship between infection susceptibility
and charge, there is also a relationship between pre infection and post-infection LOS.
The complex relationships involving LOS can be explored using path analysis.
There are 5 general steps in path analysis.[82] First, the model must be specified,
which involves formally stating the proposed model. Specification is probably the most
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important step because if the model is incorrect the results will be meaningless. Of note,
variables in path analysis need to be continuous except if the variable represents group
membership or is an exogenous variable. Categorical variables cannot be
endogenous.[82] Second, the model must be identified. Identification refers to verifying
the specific model assumptions. Similar to regression, observations need to be
independent, normally distributed and have uniform variances.[82] Third, the model is
estimated. Logistically, this occurs using a series of regression models. Many statistical
software packages are available that perform this function. Fourth, the fit of the model is
tested. The fit of the model is good if the fitting function is close to zero. If the ratio
between chi-square and the degrees of freedom is less than 2, then the model fit is
good.[83] Finally, the model can be manipulated. This can be useful especially if the
model fit is not good.
The proposed path analysis model is diagramed below in Figure 4.1. The direct
and indirect impact of one variable on another can be estimated.[82] Direct effects are
represented when a single arrow connects two variables. Indirect effects are defined
when no single line directly connects two variables, but instead, the variables are
connected through one or more other variables along their path.[84] Indirect effects
measure the impact of intermediates or mediator variables.[82] The endogenous
structural equations used that correspond to Figure 4.1 are described below in Equations
4.1 to 4.2. The model will be tested using SAS’s PROC CALIS. The model fit was
assessed using chi square.
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Figure 4.1. Path Analysis diagram
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Post-infection LOS = b31 x susceptibility status + b32 x pre-infection LOS + e3

Eq. 4.1

Charge = b43 x post-infection LOS + b42 x pre-infection LOS + e4

Eq. 4.2

Human Subjects Protection and Data Privacy
The largest potential risk for the subjects was exposure of medical information.
To ensure minimal risk to the patients, the data were coded and encrypted. The data did
not contain patients’ medical record numbers. Access to the dataset was restricted to
those individuals listed on this protocol, and the dataset was centrally maintained in a
password-protected environment. Multiple copies of the data were minimized. In the
event that additional copies of the dataset were required for the conduct of the study, the
principle investigator maintained a list of those copies and ensured that all extra copies
were appropriately destroyed once analysis was finished so that only one copy was
retained to satisfy university record keeping policies relevant to research data. Disclosure
of information did not take place without the expressed written permission of Cerner
HealthFacts or required by law. Data within HealthFacts is compliant with the Health
Insurance Portability and Accountability Act of 1996 (HIPAA). Results will be
published in such a way that no subject will be individually identifiable. This study
qualified for exemption according to 45 CFR 46.101(b) Category 4 at Virginia
Commonwealth University internal review board (IRB). (VCU IRB#: HM11841). A
copy of the IRB Approval form can be found in Appendix A.
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CHAPTER 5
Results

Data Manipulation
Data from the Cerner HeathFacts data warehouse were received as numerous files
that were cleaned by a programmer. The flow chart below (Figure 5.1) outlines the
general methodology the programmer used to extract and combine the data. Data fields
were extracted that contained the variables of interest when: (1) the patient age was
greater than 18 years old, (2) discharge date was between 2000 and 2006, (3) collection
source key of blood, and (4) isolate key for Staphylococcus aureus. Files that contained
the variables of interest were joined so that all the necessary data elements were
contained in two datasets. The first dataset contained the microbiologic information
(referred to as Micro) and the second dataset included all the other variables including
time stamped dates (referred to as Large). The programmer also deleted duplicate
observations. Only observations that contained identical information for all data
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elements were excluded here. Data were provided to the investigator in a much improved
form, but some manipulation was still required.
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Figure 5.1. Flow chart used by programmer for data retrieval

Start
Open file
Select fields of interest

Is patient age ≥ 18 years,
discharged date between 2000
and 2006, collection source key
of blood, and isolate keys for
Staphylococcus aureus,?

No

Yes
Store this Record

Is this the last record?

No

Yes
Extract all the stored records
Encrypt the file in the server, transfer it in the local
drive and then decrypt the file

Stop
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Read Next
Record

The Micro dataset contained a unique patient identified and recorded isolate
susceptibilities. These susceptibilities contained a variety of values, such as resistant,
susceptible, null and moderately sensitive. Only observations where susceptibilities were
reported as resistant or susceptible were retained in the dataset. All microbiologic
susceptibility testing was done with oxacillin or methicillin. Some patients had both a
resistant and a susceptible isolates (n=263). A flowchart describing this cleaning process
is available below (Figure 5.2).
The Large dataset contained all other data elements. Patients were excluded if
their pre-infection length of stay (LOS) was less than two days. Duplicate patients were
removed for a final Large dataset n=3,313. The Micro and Large datasets were merged
creating one dataset with 1,088 patients. A flowchart is provided below in Figure 5.2.
A substantial number of patients in both the Micro and Large datasets were
excluded during the merge since the datasets contained observations from different
hospitals. Table 5.1 below shows the number of excluded hospitals per year.
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Figure 5.2 Flow chart used by investigator for data manipulation

Micro Dataset

Large Dataset

N=3,749
(4,643 obs)

N=6,750
(415,367 obs)

Remove if
result not
R or S

Pre-infection
LOS > 2 days

N=3,538
(3,844 obs)

N=3,313
(249,449 obs)

Remove
duplicates
(R and S)

Remove
duplicate
patients

N=3,275
(3,275 obs)

N=3,313
(3,313 obs)

Merged Micro and Large datasets
N=1,088
(1,088 obs)

obs =observations
LOS=length of stay
R= Resistant
S=Susceptible
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Table 5.1 Number of Hospitals excluded by the merge of Micro and Large datasets

2000
2001
2002
2003
2004
2005
2006

Merged Dataset
(Micro + Large)
9
15
13
17
15
14
22

Large Dataset

Excluded Hospitals

9
16
18
20
19
26
32

0
1
5
3
4
12
10

Relative DRG weights, publically available through CMS, for 2006 were added
into the dataset.[65] Some DRGs from earlier years were no longer valid in 2006,
meaning the codes were no longer used. The patients with the invalid DRG codes were
removed (n=966). A Charlson comorbidity score was calculated for each patient.
After examining the pre-infection LOS distributions for MRSA (Figure 5.3) and
MSSA (Figure 5.4), frequency matching was performed. Only one MSSA observation
had a pre-infection LOS longer than 62 days (circled below in Figure 5.4). There were
eight MRSA patients excluded. Therefore, patients with a pre-infection LOS greater than
62 days were excluded from the analysis (n=957).
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Figure 5.3 Distribution of pre-infection LOS (MRSA)
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Figure 5.4 Distribution of pre-infection LOS (MSSA)
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The dataset was then examined for erroneous data points. Some observations
existed with a negative LOS. These observations were removed. Some observations
reported incredibly low charges (less than $100). There was not a previously defined
method to deal with this scenario. The data were explored but there was no apparent
pattern to the low charges. The investigator chose a reasonably prudent criterion for
inclusion that would exclude patients with an unrealistically low charge. The pilot
investigation had a minimum charge of $11,896. Patients with charges less than $11,896
and with LOS ≥ 9 days were assumed spurious and were removed. The final dataset
contained 930 observations. See Figure 5.5 below.
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Figure 5.5 Flowchart leading to final dataset

N =1,088
Removed if:
DRG was not valid in
2006
N =966
Removed if:
LOS was negative
N =948
Removed if:
total charge < $11,896
and
LOS ≥ 9 days
N =930
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Hospital charges were inflated to their 2006 value. CPI adjusted rates
(compounded annually) were calculated for each year. Table 5.2 below assumed a $1.00
reference value. Total hospital charges were adjusted to the 2006 by multiplying the
reported charge by the CPI adjusted rate. For example, 2000 values were increased by
48%, and 2001 values by 38% to estimate their 2006 value. Figure 5.6 below shows step
by step how the CPI adjusted rates were calculated. The inflation rates can be found in
Table 4.1.

Table 5.2 CPI adjusted rates
2000 to
2001 to
2006
2006
2000
1
2001
1.07
1
2002
1.16
1.09
2003
1.24
1.17
2004
1.32
1.24
2005
1.39
1.30
2006
1.48
1.38
CPI = Consumer Price Index

2002 to
2006

2003 to
2006

2004 to
2006

1
1.07
1.14
1.20
1.27

1
1.06
1.11
1.19

1
1.05
1.12

Figure 5.6 Calculation of CPI adjusted rate
2000 to 2001 had an inflation rate of 6.62%
2001 to 2002 had an inflation rate of 8.72%
Assuming the value in 2000 was $1, the value in 2001 would be:
$1.00 x (1 + 0.0662) = $1.07
The value in 2002 would be: $1.07 x (1 + 0.0872) = $1.16.
This means that the adjusted inflation rate for 2000 to 2002 was 16%.
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2005 to
2006

1
1.06

Descriptive Statistics
Demographic data for the categorical variables (admission source, payer type, and
discharge disposition) are described below in Tables 5.3. There were more categories for
each categorical variable that were collapsed. Additional categories can be found in
Appendix B. Of the 930 patients, 546 were MRSA (58.7%) and 384 were MSSA
(41.3%). There was a significant difference in admission source (χ2 = 10.43, df = 3, pvalue = 0.0152). More MSSA were admitted from the Emergency Room and more
MRSA patients were transferred to the hospital. There was also a significant difference
in discharge status (χ2 = 19.55, df = 5, p-value = 0.0015). More MSSA patients were
discharged and more MRSA patients expired in the hospital. Discharge status was
examined strictly as alive, dead or not available; 30.8% of MRSA patients expired in the
hospital compared to 21.4% of MSSA patients (χ2 = 11.92, df = 2, p-value = 0.0026). A
p-value was not calculated for the payer status since a majority of the patients had data
classified as not available. The groups were balanced with respect to gender; the MRSA
group was 53.5% male while 53.4% of the MSSA group was male (χ2 = 0.008, df = 1, pvalue = 0.9773).
Demographic data for the continuous variables can be found in Table 5.4. Data is
reported as medians and interquartile ranges since the variables were not normally
distributed. The Wilcoxon Rank Sum test indicated all continuous variables were
significantly different between the MRSA and MSSA groups except post-infection LOS.
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Table 5.3 Descriptive statistics for categorical variables (n=930)
MRSA
n (column %)

MSSA
Total
n (column %)
n
Admission Source
p-value = 0.0152
Referral
96 (17.6)
68 (17.7)
164
Transfer
55 (10.1)
19 (4.9)
74
Emergency Room
261 (47.8)
212 (55.2)
473
Not available
134 (24.5)
85 (22.1)
219
546
384
p-value = 0.0015
Discharge Status
163 (29.9)
151 (39.3)
314
Discharged
172 (31.5)
120 (31.3)
292
Transferred
16 (2.9)
9 (2.3)
25
Hospice
168
(30.8)
82
(21.4)
250
Expired
5 (0.9)
11 (2.9)
16
Other
11 (2.9)
33
22 (4.0)
Not available
546
384
Payer Type
p-value= not calculated
Insured
33 (6.0)
35 (9.1)
68
Medicare
20 (3.7)
15 (3.9)
35
Medicaid
145 (26.6)
85 (22.1)
230
Self Pay
9 (1.6)
3 (0.8)
12
Not available
339 (62.1)
246 (64.1)
585
546
384
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus
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Table 5.4 Descriptive statistics for continuous variables (n=930)
MRSA
Median
IQR
72
59 to 80

MSSA
Median
IQR
67
53 to 78

p-value
0.0003

0 to 2.00

0.0138

1.04 to 2.39
2 to 7
3 to 12
8 to 19

0.0004
<0.0001
0.6039
<0.0001

Variable
Age 1
Charlson
1.00
0 to 2.00
1.00
comorbidity score
DRG weight
1.68
1.21 to 3.07
1.35
Pre-infection LOS2
6
3 to 12
6
2
Post-infection LOS
6
2 to 14
6
2
Total LOS
15
9 to 25
12
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus
IQR = interquartile range
DRG = diagnosis related group
LOS = length of stay
1
Age was measured in years
2
LOS was measured in days
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Objective 1:
Crude difference in hospital charge by infection susceptibility

The total mean hospital charge was $111,636. The charge for each group can be
found below in Table 5.5. The crude difference in mean charge was $24,406. Using the
Wilcoxon Rank Sum, there was no difference between the MRSA and MSSA groups (pvalue < 0.0001).

Table 5.5 Crude hospital charge in US dollars
Mean
SD
Median
IQR
Minimum Maximum
Overall 111,636 241,211 59,764 30,751 121,956
3,323 3,392,801
MRSA 121,713 252,465 68,013 33,247 131,060
4,035 3,392,801
MSSA
97,307 223,781 49,199 27,338
98,898
3,323 2,957,732
US = United States
SD = standard deviation
IQR = interquartile range
MRSA = methicillin-resistant Staplylococcus aureus
MSSA = methicillin-susceptible Staplylococcus aureus

The intention was to perform repeated measures ANOVA. However, only four
hospitals had data every year from 2000 through 2006. Since four hospitals represent a
small fraction of the datasets, repeated measures ANOVA was not appropriate. Instead,
descriptive statistics were analyzed graphically to see if a difference appeared within the
study period.
Descriptive statistics for total charge by discharge year are presented below
(Tables 5.6 and 5.7). “N” represents the number of observations per year. The mean for
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2001 was much higher than any other year. The maximum values for 2001 were
$3,392,801 and $2,957,732 for MRSA and MSSA respectively. There were five extreme
values in 2001 which artificially inflated the 2001 mean. All the other observations
appeared within one standard deviation of one another. Starting in 2002, there did appear
to be a slight downward trend in the MSSA mean charge. However, this trend was not
echoed by the MRSA data.
Boxplots for the total charges per year are below in Figure 5.7. The boxplot is
labeled with the number of outliers per year. For the purposes of this figure, an outlier
was defined as above the 75th percentile. Of note are five extreme outlier observations
for 2001. They represent both MRSA and MSSA cases. In Figure 5.8, the interquartile
ranges have been enlarged to more closely examine the means which are depicted by red
triangles. The only mean that appeared different was 2001. This mean was extreme due
to five extreme outliers that will be addressed later in the analysis. An alternative
statistical test, instead of repeated measures ANOVA, was not pursued further since there
was no visually apparent difference in the means.
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Table 5.6 Descriptive statistics for total hospital charge by discharge year for MRSA
Discharge year N
Mean
2000
35
102,313
2001
115
222,773
2002
93
116,864
2003
62
103,628
2004
49
66,633
2005
67
94,264
2006
125
83,050
Overall
546
121,713
Std Dev = standard deviation
Min = minimum
Max = maximum

Std Dev
105,190
502,148
123,483
111,777
45,819
106,543
90,009
252,465

Min
10,746
8,641
6,141
4,339
14,946
4,035
4,710
4,035

Max
487,359
3,392,801
574,895
461,235
182,601
675,738
683,193
3,392,801

Table 5.7 Descriptive statistics for total hospital charge by discharge year for MSSA
Discharge year N
Mean
2000
24
68,359
2001
89
168,224
2002
69
103,714
2003
27
79,214
2004
24
76,372
2005
53
63,210
2006
98
64,030
Overall
384
97,307
Std Dev = standard deviation
Min = minimum
Max = maximum

Std Dev
46,113
431,715
108,640
65,329
93,130
82,007
79,107
223,781
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Min
4,414
9,888
10,074
5,260
3,323
7,826
4,324
3,323

Max
180,160
2,957,732
435,997
229,330
397,363
517,451
445,316
2,957,732

Figure 5.7 Boxplot of Total Charge by Discharge Year
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Figure 5.8 Boxplot of Total Charges by Discharge Year with outliers omitted
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Objective 2:
Adjusted difference in hospital charge by infection susceptibility

A GLM utilizing a gamma distribution and logarithmic link was used to estimate
total charge adjusting for potential confounders. Before a multivariable model could be
analyzed, each potential covariate was evaluated for inclusion in the model. Using total
charge as the dependent variable, the results of the univariate GLMs are available in
Table 5.8. Admission source was not considered since data were missing for 219
patients. All variables were significant at p-value < 0.25, except for discharge status,
and thus eligible for inclusion in the multivariable model. Discharge status was still
included in the multivariable model since it has been previously established as a known
confounder.
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Table 5.8 Univariate analysis (hospital charge = dependent variable)
Variable

Coefficient

0.7969
1.042

1.0684
1.078

Wald 95%
Confidence
Limits
0.7001 0.9073
0.899
1.208

0.997
1.173
0.947

1.002
1.020
1.015

0.992
1.129
0.920

1.001
1.219
0.975

0.1464
<0.0001
0.0002

1.044

1.004

1.036

1.052

<0.0001

Exponentated
Coefficient

Gender
-0.227
Discharge
0.0413
Status
Age
-0.0033
DRG weight
0.1596
Charlson
-0.0548
comorbidity
score
Pre0.0428
Infection
LOS
DRG = diagnosis related group
LOS = length of stay

Standard
Error

p-value
0.0006
0.5838

A propensity score was calculated for the hospital level factors (i.e. bed size,
urban/rural, teaching status.) The independent variable was infection susceptibility
(MRSA or MSSA) and the dependent variables were the hospital level factors.
Propensity scores were only calculated for 900 patients since 30 patients had missing
data. Goodness of fit was assessed using the Hosmer-Lemeshow goodness of fit test (χ2
= 1.6365, df = 5, p-value = 0.8968). This indicated good fit. Balance between the
MRSA and MSSA groups was reached with respect to the confounders used to calculate
the propensity score (Table 5.9). The distribution of propensity scores is below in
Figures 5.9 and 5.10.
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Table 5.9 Propensity score by confounders included in the score

Bed size
6 to 99
100 to 199
200 to 299
300 to 499
500+

MRSA

MSSA

0.65
0.41
0.38
0.41
0.41

0.62
0.44
0.39
0.43
0.42

Urban/Rural Status
Rural
0.24
Urban
0.41
Teaching Status
Non-teaching
0.38
Teaching
0.51
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptibile Staphylococcus aureus
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0.32
0.43
0.39
0.51

Figure 5.9 Distribution of propensity scores for MRSA
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Figure 5.10 Distribution of propensity scores for MSSA
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All variables in Table 5.8 were used in the initial multivariable model as well as
the calculated propensity score. Age was then removed from the model since it had a
multivariable p-value > 0.05. The results of the multivariable model, excluding age, are
below in Table 5.10. The model contained 867 observations. Propensity scores were only
calculated for 900 observations. Another 33 observations in the final sample had an
unavailable discharge status. In this and all subsequent models the variable susceptibility
refers to MRSA vs. MSSA.
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Table 5.10 Multivariable model (hospital charge = dependent variable)
Standard
Error

Wald 95% Confidence
Limits for
Exponentated
Coefficent
0.93
1.19
0.71
0.91
0.15
0.99

Parameter

Coefficient

Exponentated
Coefficient

Susceptibility
Gender
Propensity
Score
DRG weight
Charlson
comorbidity
score
Pre-infection
LOS
Discharge
Status

0.0512
-0.2179
-0.9575

1.05
0.80
0.38

1.07
1.06
1.62

0.1135
-0.0472

1.12
0.95

1.02
1.01

1.08
0.93

1.16
0.98

<.0001
0.0014

0.0413

1.04

1.00

1.03

1.05

<.0001

0.1004

1.11

1.07

0.96

1.27

0.1566

p-value
0.4277
0.0005
0.0479

Log likelihood = -10833.3650, χ2 = 2633, df = 859, n = 867, p-value < 0.0001
DRG = diagnosis related group
LOS = length of stay

All two-way interaction effects between infection susceptibility status and the five
potential modifiers (gender, DRG weight, Charlson comorbidity score, discharge status
and pre-infection LOS) were assessed by including an interaction term for each in the
multivariable model. Likelihood ratio tests were used to compare the full and reduced
models with different combinations of the interaction terms. The results are below in
Table 5.11. No significant interactions between susceptibility status and discharge status,
gender or pre-infection LOS were found. However, there were interactions between
susceptibility and DRG weight as well as susceptibility and Charlson comorbidity score.
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Table 5.11 Potential interaction terms with susceptibility (dependent variable = hospital
charge)
Variable
Main Effects Model
Susceptibility x
Charlson comorbidity
score
Susceptibility x DRG
weight
Susceptibility x Gender
Susceptibility x Preinfection LOS
Susceptibility x
Discharge status
LL = Log likelihood
df = degrees of freedom
DRG = diagnosis related group
LOS = length of stay

2LL
-21666.73
-21658.10

df

Chi-Square

p-value

1

8.63

0.0033

-21646.17

1

11.93

0.0006

-21643.33
-21640.54

1
1

2.84
2.79

0.092
0.095

-21640.20

1

0.34

0.5601

All possible interactions between the Charlson comorbidity score, pre-infection
LOS, DRG weight, gender and discharge status were assessed using likelihood ratio tests
as described above. The interaction terms were tested by adding each one sequentially in
the model. There were two significant interactions; DRG weight and pre-infection LOS
as well as gender and the Charlson comorbidity score. These interactions were retained
in the model along with the two associated lower-order terms.
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Table 5.12 Potential interaction terms among the covariates (dependent variable =
hospital charge)
Variable
2LL
Main Effects Model
-21666.73
Susceptibility x
-21658.10
Charlson
comorbidity score
Susceptibility x
-21646.17
DRG weight
DRG weight x pre-21633.75
infection LOS
Gender x Charlson
-21626.203
comorbidity score
DRG weight x
-21624.43
Charlson
comorbidity score
-21623.51
DRG weight x
discharge status
DRG weight x
-21622.72
gender
gender x discharge
-21622.02
status
Gender x pre-21621.88
infection LOS
Charlson
-21621.71
comorbidity score x
pre-infection LOS
-21621.53
Charlson
comorbidity score x
discharge status
pre-infection LOS x
-21621.53
discharge status
LL = Log likelihood
DF = degrees of freedom
LOS = length of stay
DRG = diagnosis related group

DF

Chi-Square

P-value

1

8.63

0.0033

1

11.93

0.0006

1

12.42

0.0004

1

7.54

0.006

1

1.77

0.1835

1

0.92

0.3374

1

0.79

0.373

1

0.7

0.4038

1

0.14

0.7066

1

0.17

0.6784

1

0.18

0.6727

1

0

0.9461
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The final model included susceptibility, gender, the propensity score, DRG
weight, the Charlson comorbidity score, pre-infection LOS, discharge status, and four
interaction terms (susceptibility and DRG weight, susceptibility and the Charlson
comorbidity score, gender and Charlson comorbidity score, and DRG weight and preinfection LOS). The parameter estimates were exponentiated for interpretation (Table
5.13). No pairwise multicollinearity was found.
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Table 5.13 Parameter estimates (dependent variable = hospital charge)

Parameter

Coefficient

Wald 95%
Exponentiated Standard Confidence Limits
Coefficient
Error
of Exponentiated
Coefficient
1.57
1.11
1.27
1.94
1.39
1.08
1.19
1.62
0.49
1.61
0.19
1.25

Susceptibility
0.4521
Gender
0.3306
Propensity
0.7105
Score
DRG weight
0.2487
0.55
1.29
0.33
0.90
Charlson
0.0529
0.46
1.24
0.30
0.71
comorbidity
score
Pre-infection
0.0548
1.06
1.01
1.05
1.07
LOS
Discharge
0.1062
1.11
1.07
0.97
1.27
status
Susceptibility
-0.103
1.11
1.03
1.05
1.18
x Charlson
comorbidity
score
-0.106
1.11
1.03
1.04
1.19
Susceptibility
x DRG
weight
DRG weight
-0.005
1.00
1.00
0.99
1.00
x preinfection LOS
-0.079
0.92
1.03
0.87
0.98
Gender x
Charlson
comorbidity
score
Log likelihood = -10813.1013, χ2 = 2338, df = 855, n = 867, p-value < 0.0001
DRG = diagnosis related group
LOS = length of stay
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p-value
<.0001
<.0001
0.1372
0.0174
0.0004
<.0001
0.127
0.0005

0.002
<.0001
0.006

The deviance residuals were plotted against the fitted values transformed to
constant information (Figure 5.11). The transformation to constant information is
transforming the fitted values to a constant variance scale or constant information of the
error distribution. The transformation formula for the gamma distribution is below in
Equation 5.1. This scatterplot can be interpreted analogously to a residual by predicted
plot in linear regression. Extreme values from Figure 5.11 (highlighted in red) are
described below in Table 5.14. Excluding these values from the deviance residuals by
fitted values plot yielded a random scatter.

Figure 5.11 Deviance residuals by the fitted values transformed to constant information
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Transformation to constant information = 2 x log(fitted value)
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Eq. 5.1

Table 5.14 Extreme values
MRSA
or
Gender
MSSA
MSSA
Male
MSSA
Male
MRSA
Male
MRSA
Female
MRSA
Male
LOS = length of stay

Age
72
55
67
61
55

PrePostDischarge
Charge
Infection Infection
Year
($)
LOS
LOS
8
25
2001
2,909,322.44
6
19
2001
2,957,731.55
4
57
2001
3,111,884.28
18
52
2001
2,993,126.42
29
95
2001
3,392,801.31

The above procedures were repeated without the five extreme observations
(n=925).Variables significant at p-value < 0.25 during univariate analysis were: DRG
weight, pre-infection LOS and mortality. Gender was no longer significant and not
included in the model. The Charlson comorbidity index was included even though the
univariate p-value = 0.6430 since severity of illness was a known confounder. The
multivariable model included: susceptibility, DRG weight, charlson comorbidity index,
pre-infection LOS, mortality, and the propensity score. All two-way interactions with
infection susceptibility were assessed. Only the interaction between susceptibility and
the charlson comorbidity index was significant. Interactions were assessed between all
other variables. The interaction between DRG weight and pre-infection LOS was
significant. The final model included susceptibility, the propensity score, DRG weight,
the Charlson comorbidity score, pre-infection LOS, discharge status, and two interaction
terms (susceptibility and the Charlson comorbidity score, and DRG weight and preinfection LOS). The parameter estimates were exponentiated for interpretation (Table
5.15).
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Table 5.15 Parameter estimates without extreme values (dependent variable = hospital
charge)
Wald 95%
Confidence Limits
of Exponentiated
Coefficent
1.06
1.42
0.47
2.56

Exponentated Standard
Parameter
Coefficient Coefficient
Error
0.20
1.23
1.08
Susceptibility
-0.09
1.10
1.54
Propensity
Score
0.13
1.14
1.02
1.09
1.19
DRG weight
Charlson
0.04
1.04
1.02
1.00
1.09
comorbidity
score
0.05
1.05
1.00
1.04
1.06
Pre-infection
LOS
-0.05
0.95
1.06
0.84
1.07
Discharge
Status
Susceptibility
-0.09
0.92
1.03
0.87
0.97
x Charlson
comorbidity
score
DRG weight
-0.003
1.00
1.00
1.00
1.00
x preinfection
LOS
Log likelihood = -10621.4681, χ2 = 836.06, df = 853, n = 862, p-value =0.7312
DRG = diagnosis related group
LOS = length of stay
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pvalue
0.0055
0.8265
<.0001
0.0783
<.0001
0.4174
0.0018

0.0004

Since susceptibility status was involved in an interaction with the Charlson
comorbidity score, it must be interpreted in that context. The median Charlson
comorbidity score was one and the maximum score was 12. Higher Charlson scores are
associated with a higher probability of in-patient death. Table 5.16 below outlines the
percent increase/decrease in hospital charge for infection susceptibility taking into
account the Charlson comorbidity score. As patients get more severely ill, the total
charge for MSSA patients increases while the total charge for MRSA patients decreases.
These results are also displayed in Figure 5.12. The results of the interaction term DRG
weight by pre-infection LOS are below in Table 5.17. As the pre-infection LOS
increases, the effects of the DRG weight on total charge decrease.

Table 5.16 Change in hospital charge adjusting for Charlson comorbidity score
Charlson comorbidity score

MRSA

MSSA

1

16%

4%

2

11%

8%

6

-9%

27%

12

-33%

62%

MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus

84

Table 5.17 Effect modification of DRG weight and pre-infection LOS
DRG weight

3
1
1.31
5
1.92
10
3.67
15
7.03
DRG = diagnosis related group
LOS = length of stay

Pre-infection LOS
6
9
1.39
1.62
1.09
1.01
1.18
1.02
1.29
1.03

15
2.21
1.00
1.00
1.00

Figure 5.12 Change in hospital charge adjusting for Charlson comorbidity score
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15

The multivariable model predicted an overall mean charge of $116,404. The
MRSA and MSSA mean charges are presented in Table 5.16. According to the model, a
case of MRSA bacteremia has an affiliated charge of $22,889 more than a case of MSSA
bacteremia.

Table 5.18 Predicted charges in US dollars
Overall
MRSA
MSSA
Mean
116,404
125,910
103,021
Standard Deviation
107,898
99,535
117,524
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus
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Objective 3:
Adjusted difference in LOS by infection susceptibility

A GLM utilizing a gamma distribution and logarithmic link was used to estimate
LOS adjusting for potential confounders. Before a multivariable model could be
analyzed, each potential covariate was evaluated for inclusion in the model. Objective 3
was similar to Objective 2 but used post-infection LOS as the dependent variable in the
modeling process. There were 48 observations that had a post-infection LOS equal to
zero. Zero is an invalid response value for the gamma distribution. These observations
were excluded from this objective.
Admission source was not considered since information was missing for 219
patients. The five extreme observations identified in Objective 2 were also excluded
from this analysis. The results of the univariate GLMs are available in Table 5.19. All
variables were significant at p-value < 0.25 except for gender. Age, DRG weight,
Charlson comorbidity score, pre-infection LOS and discharge status were all eligible for
inclusion in the multivariable model.
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Table 5.19 Univariate analysis (post-infection LOS = dependent variable)

Parameter

Coefficient

Gender
-0.029
Age
-0.005
DRG weight
0.086
Charlson
comorbidity
-0.049
score
Pre-infection
0.009
LOS
Discharge
0.419
Status
DRG = diagnosis related group
LOS = length of stay

Exponentated
Coefficient

Standard
Error

0.97
1.00
1.09

1.07
1.00
1.02

Wald 95%
Confidence Limits
of Exponentated
Coefficent
0.86
1.10
0.99
1.00
1.06
1.12

0.95

1.02

0.92

0.98

0.0019

1.01

1.00

1.00

1.02

0.0083

1.52

1.07

1.32

1.75

<.0001

p-value
0.6427
0.0133
<.0001

The same propensity score calculated above for Objective 2 was used again to
account for differences in hospital level factors (i.e. bed size, urban/rural, teaching
status.) All variables in Table 5.19, excluding gender, were used in the initial
multivariable model as well as the calculated propensity score. Age was then removed
from the model since it had a multivariable p-value >0.05 (p=0.0991). The results of the
multivariable model, excluding age, are below in Table 5.20.
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Table 5.20 Multivariable model (post-infection LOS = dependent variable)

Parameter

Coefficient

Exponentated
Coefficient

Standard
Error

Wald 95%
Confidence Limits
of Exponentiated
Coefficient
0.97
1.26
1.36
9.19

Susceptibility
0.10
1.11
1.07
Propensity
1.26
3.54
1.63
Score
DRG weight
0.07
1.07
1.02
1.04
1.11
Charlson
-0.04
0.96
1.02
0.93
1.00
comorbidity
score
Pre-infection
0.01
1.01
1.00
1.00
1.02
LOS
Discharge
0.38
1.47
1.07
1.27
1.69
Status
Log likelihood = -2633.4724, χ2 = 1078, df = 807, n = 814, p-value < 0.0001
DRG = diagnosis related group
LOS = length of stay

p-value
0.12
0.01
<.0001
0.03
0.01
<.0001

All two-way interaction effects between infection susceptibility status and the
four potential modifiers (DRG weight, Charlson comorbidity score, discharge status and
pre-infection LOS) were assessed by including an interaction term for each in the
multivariable model. Likelihood ratio tests were used to compare the full and reduced
models with different combinations of the interaction terms. The results are below in
Table 5.21. Neither discharge status, DRG weight nor the Charlson comorbidity score
had significant interactions with susceptibility status. However, there was a significant
interaction between susceptibility and pre-infection LOS.
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Table 5.21 Potential effect modifiers of interaction susceptibility
Variable
2LL
Main Effect Model
-5266.9
Susceptibility x pre-5261.2
infection LOS
Susceptibility x DRG
-5260.8
weight
-5258.6
Susceptibility x
Charlson comorbidity
score
Susceptibility x
-5258.6
discharge status
LL = Log likelihood
DF = degrees of freedom
DRG = diagnosis related group
LOS = length of stay

DF

Chi-Square

P-value

1

5.73

0.0167

1

0.39

0.5333

1

2.18

0.1395

1

0.03

0.8684

All possible interactions between the Charlson comorbidity score, pre-infection
LOS, DRG weight, and discharge status were assessed using likelihood ratio tests as
described above. There was one significant interaction; susceptibility and pre-infection
LOS. The interaction was retained in the model along with the associated lower-order
terms.
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Table 5.22 Identification of interactions (dependent variable = post-infection LOS)
Variable
2LL
Main Effects Model
-5266.9
Susceptibility x pre-5261.2
infection LOS
Charlson comorbidity
-5255.1
score x pre-infection LOS
DRG weight x discharge
-5254.3
status
Charlson comorbidity
-5253.1
score x discharge status
DRG weight x Charlson
-5252.8
comorbidity score
Pre-infection LOS x
-5252.5
discharge status
LL = Log likelihood
DF = degrees of freedom
DRG = diagnosis related groups
LOS = length of stay

DF

Chi-Square

P-value

1

5.73

0.0167

1

6.09

0.0136

1

0.83

0.3625

1

1.18

0.2775

1

0.29

0.5934

1

0.31

0.5806
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The final model included susceptibility, the propensity score, DRG weight, the
Charlson comorbidity score, pre-infection LOS, discharge status, and two interaction
terms (susceptibility and pre-infection LOS and pre-infection LOS and Charlson
comorbidity score). The parameter estimates were exponentiated for interpretation
(Table 5.23). Pairwise multicollinearity was assessed. The only multicollinearity that
existed was between pre-infection LOS and the interaction term between susceptibility
and pre-infection LOS. This collinearity was expected since both terms take into account
pre-infection LOS.
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Table 5.23 Parameter estimates (dependent variable = post-infection LOS)

Exponentiated Standard
Coefficient
Error

Wald 95%
Confidence
Limits of
P-value
Exponentiated
Coefficients
0.80
1.13 0.5715
1.40
9.31 0.0078

Parameter

Coefficient

Susceptibility
Propensity
Score
DRG weight
Charlson
comorbidity
score
Pre-infection
LOS
Discharge
Status

-0.05
-1.285

0.95
3.61

1.09
1.62

0.0716
0.0037

1.07
1.00

1.02
1.02

1.04
0.96

1.11 <.0001
1.05 0.8707

0.1697

1.18

1.06

1.05

1.33 0.0044

0.3625

1.44

1.07

1.25

1.66 <.0001

Susceptibility
-0.021
0.98
1.01
0.96
0.99 0.0091
x preinfection
LOS
Charlson
-0.004
1.00
1.00
0.99
1.00 0.0093
comorbidity
score x preinfection
LOS
Log likelihood = -2627.5613, χ2 = 832, df = 805, n = 814, p-value = 0.2476
DRG = diagnosis related groups
LOS = length of stay
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There was an interaction between infection susceptibility and pre-infection LOS.
As pre-infection LOS increased, the post-infection LOS for MSSA patients increased
more than MRSA patients (Table 5.24). There was also an interaction between preinfection LOS and Charlson comorbidity score (Table 5.25). Figure 5.13 depicts the
interaction between susceptibility status and pre-infection LOS.

Table 5.24 Relative increase in post-infection LOS adjusting for pre-infection LOS
Pre-infection LOS

MRSA

MSSA

2

1.28

1.40

6

2.32

2.77

9

3.63

4.61

12

5.66

7.66

20

18.59

29.78

LOS = length of stay
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus

Table 5.25 Effect modification of Charlson comorbidity score and pre-infection LOS
Charlson
Comobidity
score
3
1
1.65
3
1.01
6
1.02
12
1.05
LOS = length of stay

Pre-infection LOS
6
2.74
1.00
1.00
1.00

9
4.46
1.00
1.00
1.00
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15
11.72
1.00
1.00
1.00

Change in Mean Post‐infection LOS
(days)

Figure 5.13 Relative increase in post-infection LOS adjusting for pre-infection LOS
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The multivariable model predicted an overall mean post-infection LOS of 9.86
days. The MRSA and MSSA mean post-infection LOSs are presented in Table 5.26.
According to the model, a case of MRSA bacteremia has an affiliated post-infection LOS
of 1.30 days more than a case of MSSA bacteremia.

Table 5.26 Predicted post-infection LOS in days
Overall
9.86
4.16

MRSA
10.40
4.99

MSSA
9.10
2.39

Mean
Standard Deviation
LOS = length of stay
MRSA = methicillin-resistant Staphylococcus aureus
MSSA = methicillin-susceptible Staphylococcus aureus
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A deviance residual against fitted values transformed to a constant scale plot was
examined. As stated in the above objective, this plot can be interpreted similarly to a
residual by predicted plot in regression. The points should look randomly scattered. In
Figure 5.14, there appeared to be a striped pattern. No changes were made to the model
but the model implications will be addressed in the discussion.

Figure 5.14 Deviance residuals by the fitted values transformed to constant information
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Objective 4:
Using path analysis to explore the relationship between susceptibility, LOS and total
hospital charge
PROC CALIS was used to assess the proposed path analysis model in Figure 4.1.
Post-infection LOS was modeled as an intermediate step and total hospital charges were
analyzed. Maximum likelihood estimation for model fitting was used. The convergence
criterion was satisfied indicating starting values were successfully calculated by the
software. The five extreme observations identified in the previous objectives were
excluded from this analysis as well (n = 925). A correlation matrix was calculated to
verify the association between the variables (Table 5.27). Post-infection LOS and total
charge were the most highly correlated variables.

Table 5.27 Correlation matrix
Susceptibility
Susceptibility
Pre-infection
LOS
Post-infection
LOS
Total Charge
LOS = length of stay

Pre-infection
LOS

Post-infection
LOS

Total
Charge

1
0.1468

1

0.0598

0.0772

1

0.1072

0.4234

0.4872

1

There were two exogenous variables (susceptibility and pre-infection LOS). They
were assumed to be correlated. Therefore, a covariance was modeled and calculated for
susceptibility and pre-infection LOS. A covariance between exogenous variables means
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the variables arose from common causes not modeled in the path diagram. There were
two endogenous variables (post-infection LOS and charge) and their variances were also
modeled.
The standardized estimates are below in Table 5.28. Unstandardized coefficients
were not calculated since SAS used a correlation matrix for data input. Also in Table
5.28 are the R2 values and the proportion of unexplained variance (1-R2) for each
outcome variable. The proportion of explained variance ranged from 1% for postinfection LOS to 39% for total charge.
The variances and covariance for the exogenous variables are in Table 5.29. The
variances for susceptibility and pre-infection LOS were one by convention. This allowed
SAS to estimate just the variance of the endogenous variables. (The variances of
endogenous variables are considered exogenous by definition.) The covariance between
susceptibility and pre-infection LOS was 0.14682. This was the correlation between the
two variables and can be interpreted similar to a Pearson correlation.
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Table 5.28 Path Analysis: Regression Coefficients
Outcome
Post-infection LOS
Total charge

Predictors
Susceptibility
Pre-infection
LOS
Post-infection
LOS
Pre-infection
LOS

Standardized
Coefficient
0.0495
0.0699
0.4573

R2

1-R2

0.01

0.99

0.39

0.61

0.3881

LOS = length of stay

Table 5.29 Variances of exogenous variables
Variance
Susceptibility
Pre-infection LOS
Post-infection LOS
Total charge
Covariance
Susceptibility & Pre-infection LOS
LOS = length of stay

Estimate
1
1
0.99165
0.61286

Standard Error
0.04652
0.04652
0.04614
0.02851

0.14682

0.03325

Table 5.30 illustrates the direct, indirect and total effects of each causal variable.
A direct effect is one variable’s influence on another not taking into account other
factors. An indirect effect is one variable’s influence on another through a mediating
variable. Total effects are the sum of the direct and indirect effects.[85] The total effect
of pre-infection LOS on total charge was 0.42. The total effect of post-infection LOS on
charge was 0.46. Susceptibility only had a 0.02 total effect on charge and a 0.05 total
effect on post-infection LOS. Pre-infection LOS had a 0.07 total effect on total charge.
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Table 5.30 Decomposition of effects
Endogenous variable
Post-infection
Total Charge
LOS

Causal Variable
Susceptibility
Direct effect
Indirect via post-infection LOS
Indirect via pre-infection LOS
Total effect

0.0495
0.0103
0.0598

Pre-infection LOS
Direct effect
Indirect via post-infection LOS
Indirect via susceptibility
Total effect

0.0699
0.0073
0.0772

Post-infection LOS
Direct effect
Total effect
LOS = length of stay

0.0226
0.05698
0.0796
0.3881
0.032
0.0033
0.4234
0.4573
0.4573

Figure 5.15 depicts the standardized estimates within the structural equation
model. By convention, the variances of the exogenous variables are not shown in the
diagram of the path model. These are the same estimates above in Table 5.28.
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Figure 5.15 Path Analysis model with standardized estimates
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The above model had adequate fit (χ2 = 0.8115, df = 1, p-value = 0.3677).
Because pre-infection LOS, post-infection LOS and charge are all skewed, significance
tests that take into account non-normal distributions were used. Other methods to assess
model fit can be found below in table 5.27. Specifically, the elliptic correlated chi-square
and the Bentler and Bonnett’s non-normed index adjust for non-normal distributions.
Table 5.26 also contains other commonly used significance tests to evaluate goodness of
fit, their value for this model, and the interpretation of that statistic.[86] All the statistical
tests concur that the path analysis model tested had adequate fit.
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Table 5.31 Path Analysis: Assessment of Fit
Statistical Test

Model
Interpretation
Statistic
0.9996 Values close to 0.90 represent a good fit

Goodness of Fit Index (GFI)
GFI Adjusted for Degrees of
Value adjusted for df, with 0.90 a good model
0.9956 fit
Freedom (AGFI)
Parsimonious GFI
0.1666 Used to compare between models
Chi-Square
0.8115
p-value greater than 0.05 indicates good fit
Chi-Square DF
1
p-value > Chi-Square
0.3677
Values less than 0.05 indicates a good model fit
RMSEA Estimate
0
Elliptic Corrected Chi-Square 0.3101
p-value greater than 0.05 indicates good fit p-value > Elliptic Corrected
0.5776 adjusts for kurtosis
Chi-Square
Bentler & Bonett's Non1.0024 Value close to 0.9 reflects a good model fit
normed Index
.RMSEA = root mean squared error approximation
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CHAPTER 6
Discussion

Review of Study Objectives
There were four general objectives of this investigation. The crude difference in
total hospital charges was determined for bacteremias caused by MRSA versus those
caused by MSSA. The impact of methicillin resistance in Staphylococcus aureus
bacteremia was examined separately for dependent variables (1) total hospital charges
and (2) post-infection LOS while adjusting for confounding. Finally, the relationships
between infection susceptibility, LOS, and total hospital charges were examined.

Summary of Findings
Objective 1 examined the crude difference in total hospital charge. The overall
mean hospital charge was $111,636. The mean charge for MRSA was $121,713 and
$97,307 for MSSA. Using the Wilcoxon signed rank test, the difference between the
total MRSA and MSSA charge was significant. The median overall charge was $59,764,
which can be separated into a median MRSA charge of $68,013 and a median MSSA
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charge of $27,338. The mean values are at the upper end of the interquartile range which
affirms the highly skewed nature of charge data.
According to the multivariable model in Objective 2, the overall mean charge was
$116,404, which can be divided into $125,910 for MRSA and $103,021 for MSSA. The
difference in MRSA charge over MSSA charge was $22,889. There was an interaction
between susceptibility and Charlson comorbidity score. This means that susceptibility
results must be interpreted in the with respect to the Charlson comorbidity score. The
above estimates are for the mean Charlson score of 1.72. This means the above estimates
are for the average patient who had a low chance of dying within the year.
Objective 3 was very similar to Objective 2 except the dependent variable was
post-infection LOS instead of total charge. The overall mean LOS was 9.9 day which
can be broken down into 10.4 and 9.1 days for MRSA and MSSA respectively. The
difference was 1.3 days. The crude post-infection LOS estimates were not significantly
different. There was an interaction between susceptibility and pre-infection LOS.
Therefore, the susceptibility results must be interpreted with pre-infection LOS. The
above estimates are for the mean pre-infection LOS of 8.6 days.
In Objective 4, a path analysis model examined more closely the relationship
between infection susceptibility, pre-infection LOS and post-infection LOS. The overall
model fit was good (χ2 = 0.8115, df = 1, p-value = 0.3677). The model predicted 39% of
the variability in total charge but only 1% of the variability on post-infection LOS. The
standardized direct and indirect effects of each variable were considered. Susceptibility
status was not highly correlated with total charge or post-infection LOS. This implies
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that susceptibility status may not strongly influence charge or post-infection LOS through
the proposed model.

Discussion of Results by Objective
Objective 1
The crude charges for MRSA and MSSA were $121,713 and $97,307
respectively. This represents a mean crude difference of $24,406, which is higher than
previously reported data. Most of these investigations reported costs. As previously
discussed, charges are known to overestimate actual costs. Mean charges are reported in
this investigation since economists are interested in means by convention.[32]
Economists care about means since they can be extrapolated from a sample to the
population. However, medians are also reported since it is the measure of central
tendency that corresponds to skewed data.
The median overall charge was $59,764, which can be separated into a median
MRSA charge of $68,013 and a median MSSA charge of $27,338. The median MRSA
charge was over twice the median MSSA charge. Cosgrove et al.[11] reported only a
1.36-fold increase in median MRSA charge over MSSA.
The pilot investigation that analyzed data from one hospital had an overall crude
median charge of $140,396, which was broken down as $166,901 for MRSA and $86,130
for MSSA. These values are over twice the median total charge reported in this
investigation. This difference in estimates is substantial. One possible explanation is that
the pilot included only patients from a tertiary care facility. These patients may be more
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severely ill than patients in other facilities that were included in this investigation.
Another possible reason for the increased charge from the pilot investigation stems from
the study period. This investigation adjusted total charge to 2006 dollars while the pilot
included 2007 values. Inflating this investigation’s total charges to 2007 dollars would
increase the estimates, but not enough to account for the entire charge disparity.
However, both investigations indicate that MRSA bacteremias are more expensive than
MSSA bacteremias.
It was intended to use repeated measures ANOVA to examine trends in hospital
charge over the study period. However, only four hospitals had data for every study year.
SAS used only these four hospitals to calculate the repeated measures ANOVA.
Extrapolating these results to the entire study population would be inappropriate. Instead
the data were examined descriptively; 2001 was the only year that seemed drastically
different. This was due to five extreme observations that were excluded from the
analysis during objective two. (See Objective 2 for a more complete discussion of the
extreme observations.)
A post-hoc analysis was performed using a generalized estimating equations
(GEE) approach to compare total hospital charge over the study period while accounting
for the hospital groupings within the dataset. The GEE model used a gamma distribution
and log link. No difference was seen in total charge per year during the study period. An
interaction term was used to test whether there was a difference in MRSA vs. MSSA total
charge throughout the study period. No difference was found. Therefore, it can be
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concluded that the total charges and the total charges for MRSA and MSSA were not
statistically different during each year of the investigation.

Objective 2
A multivariable model was used to determine the role susceptibility played on
total hospital charges. Along with potential confounders, a propensity score was included
in the model as a way to account for hospital differences (e.g., teaching status, bed size,
and urban/rural). A recent meta-analysis identified key components necessary for any
investigation using propensity scores.[87] Important components included sufficient
events per variable (EPV), continuous variable conformity with linear gradient,
interactions, collinearity, assessment of model fit, discrimination of the model, balance
achieved between the confounders, and adjustment methodology. In a logistic model,
there need to be at least 10 observations per variable.[88-90] This rule of thumb has also
been generalized to propensity scores to assure sufficient EPV. This investigation used
only 3 variables for more than 900 observations. Continuous variable conformity relates
to continuous variables used to create the propensity score. All the variables used to
create the propensity score were categorical. Therefore, it was not possible to evaluate
collinearity. Fit was assessed using the Hosmer-Lemeshow goodness of fit statistic. A
non-significant p-value was obtained indicating a lack of evidence suggesting the model
did not fit the data well. Assessment of fit relates closely to balance between the
treatment groups. The MRSA and MSSA groups appeared to be balanced by the
variables used to calculate the propensity score (Table 5.9). Propensity scores from a
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poorly fit model and without balance between the treatment groups could lead to biased
estimates of treatment effect. The propensity score used in this analysis had adequate fit
and was balanced between the treatment groups.
Propensity scores can either be used as continuous variables or stratified into
quintiles. Since there was a lot of overlap between the MRSA and MSSA groups with
respect to propensity scores, the scores were used as a continuous variable in the second
stage regression model. In a post hoc fashion, propensity score quintiles were run with
the final multivariable model. Less than a 1% change occurred in the susceptibility
parameter estimate. This indicates using the propensity score as a linear variable was not
inappropriate. Of note, when the observations were separated into quintiles based on
propensity score, it was observed that no observations existed in the 3rd quintile.
Although unusual, this was thought to be a function of the cluster distribution of scores.
Most likely this was caused by the propensity score being composed entirely of
categorical variables with few categories.
After the model was initially fit, an analysis of residuals was conducted. Residual
analysis is used in regression to identify a model specification problem or
nonhomogeneous variance.[91] For the gamma distribution, it is recommended that
deviance residuals be plotted against the fitted values transformed to the constant
scale.[92] This plot should look like a random splatter of points. There were five
observations that stood out from the rest as extreme (Figure 5.11).
Extreme values identified by the deviance residual plot were examined more
closely. They were a mixture of MRSA and MSSA observations all from the same
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hospital and same study year (2001). Removing all data points from that hospital was
considered but there were many observations from various study years that were not
extreme. Leaving the five observations in the dataset was also considered. As previously
discussed, the charge data was expected to have a long right tail. Having a handful of
large charge data points was anticipated. But, the magnitude of the five extreme
observations was astronomical. It was decided to remove these five observations for the
remainder of the analysis. The model was re-run excluding these observations.
Adjusting for confounders, the overall mean charge was $116,404, which can be
divided into $125,910 for MRSA and $103,021 for MSSA. The difference in MRSA
charge over MSSA charge was $22,889. These estimates adjusted for propensity score,
DRG weight, the Charlson comorbidity score, pre-infection LOS, discharge status and the
interaction between susceptibility and the Charlson comorbidity score as well as the
interaction between DRG weight and pre-infection LOS.
Since susceptibility status was involved in an interaction with the Charlson
comorbidity score, it must be interpreted in that context. The median Charlson
comorbidity score was one and the maximum score was 12. The interquartile range was
from 0 to 2. As a reminder, higher Charlson scores are associated with a higher
probability of in-patient death. Figure 5.12 graphically depicts the relationship between
susceptibility status and the Charlson comorbidity score. For most patients (Charlson
comorbidity score 0 to 2) MRSA bacteremias have a higher total charge than MSSA
bacteremias. But as the Charlson comorbidity score increases, the total charge for MSSA
infections increases while the total charge for MRSA infections decreases. One possible
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explanation is that MRSA patients may be expiring pre-maturely in the hospital causing
them to have a truncated charge.
There was also an interaction between DRG weight and pre-infection LOS (Table
5.17). Interpretation of this interaction showed that as pre-infection LOS increased, the
total charge was less dependent on the DRG weight. For example, a patient with a preinfection LOS of three days had highly variable charges depending on DRG weight. (A
higher DRG weight had a higher total charge.) But the effects of DRG weight
diminished as pre-infection LOS increased. Since DRG weight was one method that
controlled for severity of illness it can be suggested that severity of illness was less
important to total hospital charge as pre-infection LOS increased.

Objective 3
Objective 2 demonstrated that pre-infection LOS was more influential on total
charge as it increased than severity of illness. Susceptibility status was examined to see if
it could predict post-infection LOS similarly to total charge. The same main effects were
used in the LOS multivariable model as the model with total charge as the outcome
variable. Although the main effect of susceptibility status was not significant in the
multivariable model, there was a significant interaction with pre-infection LOS. For
MRSA and MSSA patients the post-infection LOS increased as pre-infection LOS
increased but, the post-infection LOS increased more for MSSA patients than MRSA
patients as pre-infection LOS increased. The mean post-infection LOS for MRSA
patients was not much different than for the MSSA bacteremia patients. However, a
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difference in post-infection LOS becomes apparent as pre-infection LOS increases
(Figure 5.13).
There was also an interaction between pre-infection LOS and the Charlson
comorbidity score (Table 5.24). As the Charlson comorbidity score increased, the effect
of pre-infection LOS decreased. The median Charlson score was 1 (IQR = 0 to 2). For
most patients, pre-infection LOS has a large impact on post-infection LOS. But for
patients whose Charlson score was outside the IQR, pre-infection LOS does not have
much effect on post-infection LOS.
The multivariable model adjusted for the propensity score, DRG weight, the
Charlson comorbidity score, pre-infection LOS, discharge status and the interaction
between susceptibility and pre-infection LOS as well as the interaction between Charlson
comorbidity score and pre-infection LOS. The overall mean LOS was 9.86 day, which
can be broken down into 10.4 and 9.1 days for MRSA and MSSA respectively. The
difference was 1.3 days. These estimates are for the mean pre-infection LOS of 8.59
days.
After the multivariable model was calculated, an analysis of residuals was
conducted. The deviance by residual plot could have looked better (Figure 5.14). There
appeared to be a stripped pattern. This could indicate model misspecification or
nonhomogeneous variance. Most likely the problem related to the distribution and link
functions used for the model. A logarithmic transformation of the data did not make
post-infection LOS look “normal.” It has been suggested that the Inverse Gaussian
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distribution, with a high initial peak and long right tail may be more appropriate for LOS
data.[93] Different distributions and link functions were not explored.

Objective 4
Based on the results from Objectives 2 and 3, the question then becomes whether
the increase in total hospital charge for MRSA bacteremia patients is purely a function of
LOS. Path analysis was used to evaluate the joint effects of susceptibility, pre-infection
LOS, post-infection LOS and charge. The standardized regression coefficients can be
interpreted as correlation coefficients.[82] Susceptibility status had a direct effect of
0.0485 on post-infection LOS and an indirect effect on total charge of 0.0226. Preinfection LOS had a direct effect on post-infection LOS of 0.0699. Pre-infection LOS
had a direct effect of 0.3881 on charge and an indirect effect of 0.032 through postinfection LOS for a total effect of 0.4201. Post-infection LOS had a direct effect on
charge of 0.4573.
Standardized path coefficients with an absolute value less than 0.10 are
considered to have a small effect. Values around 0.30 have a medium effect and values
greater than 0.5 are considered to have a large effect. [94] The path between
susceptibility and post-infection LOS and the path between pre-infection LOS and postinfection LOS both have small effects. This implies that the susceptibility status (MRSA
vs. MSSA) had little impact on post-infection LOS or total charge. The path from postinfection LOS to total charge had a large effect. Also, the total effect of pre-infection
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LOS on charge was medium to large. This suggests (as Objectives 2 and 3 indicated) that
pre-infection and post-infection LOS have a large impact on total charge.
SAS output produced only standardized results. The biggest advantage of
standardized results is that they can be directly compared across variables.
Unfortunately, by standardizing the regression coefficients the results lose their original
units. Unstandardized results yield estimates in their original metrics but cannot be
directly compared across variables. SAS does not produce unstandardized estimates
because the path analysis input was based on the correlation matrix. Since the input (the
correlation matrix) is already standardized, unstandarized estimates cannot be produced.
Epidemiologists are most often concerned with the magnitude of association where
unstandardized estimates are preferred.[82] However, this analysis was designed to
estimate how much each variable contributed to the other variables in the model. In this
case, interpretation of standardized regression coefficients was appropriate.
Like other statistical techniques, path analysis relies on certain assumptions. SAS
used maximum likelihood estimation to calculate the regression coefficients. This
technique requires the data to be normally distributed. Transformation of the data was
considered. Although a logarithmic transformation made the charge data normal, it did
not have the same effect on LOS. Another approach, which was executed, was to move
forward with the non-normally distributed but carefully consider the implications on the
model. First, the parameter estimates could be biased. With a large sample size,
however, parameter estimates are assumed to be fairly accurate.[94] The bigger problem
is that significance tests tend to be significant too often. Put another way, the true model
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may be rejected too frequently (Type I error).[95] The significance testing problem was
addressed by using corrected test statistics such as the elliptic correlated chi-square. If
the goodness-of-fit tests had indicated poor fit, this would have meant the model did not
explain the associated correlation well.
Another problem with this analysis is the independence assumption. Path analysis
assumes independence. However, the observations in this analysis came from different
hospitals. Patients within the same hospital are not independent. Previous research
indicates that having dependent data leads to goodness-of-fit tests that are too
conservative. In the same investigation it was noted that the parameter estimates appear
minimally biased despite their dependence.[96]
As previously discussed, the last step of path analysis is to manipulate the model.
The fit was good, so this model was not manipulated. One possibility would have been to
trim the model. Small effect path coefficients can be essentially removed from the model
and the model can be evaluated. Susceptibility had the smallest effect and would be the
first variable trimmed from the model. This implies that having a MRSA vs. a MSSA
bacteremia had a small impact total charge.
The model accounted for 39% of the variability in total hospital charge and it
accounted for only 1% of the variability on post-infection LOS. Although the model fit
was good, much of the variability in charge and post-infection LOS was unexplained.
This implies the absence of important factors in the relationship between charge,
susceptibility and LOS. The two most obvious factors that were missing are severity of
illness and discharge status/mortality. Including these factors would probably have
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accounted for more variability. Also, including these confounders may have changed the
correlation coefficient between susceptibility status and post-infection LOS and total
charge. Future path models should include these confounders.
Path analysis allows for the testing of structural models developed based on a
priori assumptions about the direct and indirect relationship between variables.
However, the structural model being tested must be based on theoretical assumptions.
The model assumed susceptibility status had an effect on total charge. The model was
not rejected but this does not prove that having MRSA vs. MSSA leads to higher charges.
Failure to reject a path model does not prove that it is correct.

Practical Implications
This investigation confirms previous single-center analyses that reported MRSA
bacteremia is more expensive than MSSA bacteremia. These results were found in both
the crude analysis and the multivariable model. The multivariable model controlled for
known confounders (i.e., DRG weight, Charlson comorbidity score, discharge status, preinfection LOS and hospital level factors). While controlling for confounders, the
predicted hospital charge was still higher for MRSA than MSSA.
Why would MRSA bacteremias be associated with higher total charges as
compared to MSSA bacteremias? As previously discussed several single center reports
have reported MRSA bacteremia being associated with a higher cost/charge than MSSA
bacteremia. There are several possible explanations for this phenomenon: MRSA and
MSSA patients are different, the MRSA and MSSA organisms are different, or their
116

treatments have very different charges. These three possibilities are discussed more fully
in the following paragraphs.
The most obvious difference between MRSA and MSSA patients is severity of
illness. Although this investigation attempted to control for severity of illness using the
Charlson comorbidity score and DRG weights, there may still have been uncontrolled
disparity in patients underlying disease status. For example, a patient with endocarditis is
not necessarily comparable to a patient with a simple bacteremia. The patient with
endocarditis will most likely be sicker and require more resources. However, the use of
DRG weights should help control for this dissimilarity since the patient with endocarditis
should have a higher relative weight.
Another potential explanation is that the MRSA and MSSA organisms are
different. The inequality in total hospital charge could be that MRSA is more virulent
than MSSA. If MRSA bacteremia were more virulent, these patients would require
longer hospitalizations and more resources. This would make their hospital stays more
expensive. However, there is currently no evidence in the literature to suggest that
hospital-onset MRSA infections are more virulent than their MSSA counterparts.[97, 98]
Host differences are not thought to be the cause of charge disparity.
Alternatively, MRSA and MSSA bacteremia patients may have different
treatments factors, which cause MRSA bacteremia patients to have a higher total charge.
These factors include (1) decreased effectiveness of pharmacologic treatment (2) a delay
in effective treatment while waiting for microbiologically effective antimicrobials (3) an
increased need for surgery or other procedures. Vancomycin has been the drug of choice
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for treating MRSA bacteremia. However, vancomycin has shown to have decreased
effectiveness in treating MRSA bacteremia.[99] Newer antibiotics are available (e.g.,
quinupristin–dalfopristin, linezolid, daptomycin and tigecycline) but there are limited
data regarding their efficacy as compared to vancomycin in treating MRSA
infections.[100] Lodise et al. found that delayed treatment was associated with a longer
duration of hospitalization (20 vs. 14 days, p-value = 0.05).[101] This is important since
previous investigations have reported that roughly 35% of patients with MRSA
bacteremia do not receive appropriate empiric therapy.[102, 103] MRSA patients also
have an increased need for surgery and other procedures resulting from the resistant
infection.[55] However, the use of DRG weights should account for differences in
surgeries and procedures as long as the complication was severe enough to merit a DRG.
The exception to this would be procedures not captured by an individual DRG. For
example, vancomycin requires blood levels to be taken to monitor the drug’s trough
concentrations. Repeated blood levels are an extra charge that MSSA patients would not
incur. There is not a DRG for blood draws. Additional surgeries should be accounted for
by DRG weight but minor procedures may not, which could result in a discrepancy of
total charge.
Another consideration about treatment differences relates to inter-hospital
variability. Although guidelines advise standards of care, different hospitals have their
own standard operating procedures. For example, researchers at Duke Medical Center
recommend using transesophageal echocardiography (TEE) to determine the length of
treatment for uncomplicated catheter-associated Staphylococcus aureus bacteremia.[104]
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This diagnostic step is not universally practiced to determine duration of treatment. Also,
different hospitals have different infection control policies.[4] Even within a hospital,
infection control policies may have changed during the study period. The impact of
inter- and intra-hospital variability should be minimal since there was not a significant
difference in total charge (overall or by susceptibility status) over the study period as
evidenced by the GEE model.
From a hospital administrator’s perspective, the results of this investigation are
important. The increased total charge for MRSA vs. MSSA bacteremia was roughly
$23,000 per case. Charges are known to over-inflate costs; a conservative increase of
hospital cost could be approximated at $11,000 per case. If a hospital had 100 MRSA
bacteremias per year, this represents an additional $1,100,000 spent on MRSA
bacteremias. The cost of an infection control program can be compared to this figure. If
an infection control program costs $500,000, the hospital would have a net savings. If
the infection control program costs $1,200,00, more factors may need to be considered.
When considering whether to spend hospital resources on an infection control program,
the cost of the program must be weighed against the potential savings of preventing a
resistant infection.
Furthermore, the argument has been made that the calculated “cost of resistance”
underestimates the true burden of resistance.[105] Additional costs may include home
intravenous therapy, an extended care facility and/or costs of rehabilitation.[106]
Providing outpatient intravenous therapy would involve the medication costs, nursing
time, supplies, laboratory tests, intravenous line placement and management. Since this
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study was conducted from the hospital’s perspective, the additional cost of managing
MRSA vs. MSSA bacteremia outside of the hospital was not considered.
The effects of mortality on total charge merit further discussion. In this
investigation the 30.8% of MRSA bacteremia patients expired in the hospital as
compared to 21.4% of MSSA patients (χ2 = 11.92, df = 2, p-value = 0.0026). A metaanalysis demonstrated a significant increase in mortality associated with MRSA
bacteremia relative to MSSA bacteremia (OR = 1.93, p-value < 0.001).[20] However
increased mortality could either increase or decrease total hospital charge. If the patient
died sooner the hospital stay charge would be truncated. However, the patient could have
complications prior to death which would lengthen the hospital stay. A drawn out
hospital stay ending in death could increase total charge, especially if significant
treatments and procedures were conducted surrounding the end-of-life period. Since this
investigation had a large sample size, the overall effects of extended and truncated LOS
was assumed to be minimal.
The results of this study should have good external validity. This was a multihospital investigation that included hospitals of various size and teaching status.
However, the study population was refined to make the MRSA and MSSA groups as
similar as possible with respect to known confounders. The purpose of this data
manipulation was to isolate the effect of infection susceptibility on total charge and postinfection LOS. By excluding outliers the generalizability does decrease. These
exclusions were necessary to maximize internal validity. For example, MRSA patients
with pre-infection LOS longer than 62 days were excluded from the analysis. These data
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points were not excluded because they were believed to be erroneous. They were
excluded because MRSA patients had a pre-infection LOS only this long (except for 1
MSSA patient.) In reality, patients do have pre-infection LOSs longer than 62 days
before contracting MRSA. Excluding these patients illustrates the trade-off between
internal and external validity. However, the effects of excluding these patients should
bias the results toward the null. Since a significant difference was found between total
charges, including these patients would have made the difference in charge greater. By
decreasing the pre-infection LOS for the MRSA group, the difference in overall total
charge was conservative.

Limitations
Admittedly, there were limitations to this investigation. Different hospitals have
varying infection control policies, formularies/protocols, and/or provide dissimilar levels
of additional education regarding proper selection of initial antibiotic therapy. This was a
limitation since the costs of these programs would affect each hospital’s total charges
differently. Additionally, the incidence of MRSA infections can be reduced substantially
through prevention.[62] The role of infection control was not addressed since that
information was not available within the Cerner HealthFacts data warehouse. Hospital
level factors were used in an attempt to control for inter-hospital variability.
This analysis was based on two fundamental assumptions. First, the charges prior
to infection onset were comparable between the MRSA and MSSA groups. Only one
charge was provided for the entire hospitalization. Charges were not available as pre121

and post-infection charges. Differences in pre-infection charges could bias the study
results. Specifically, the difference in total hospital charge would be overestimated if
pre-infection charges were higher in the MRSA group. The difference would be
underestimated if the pre-infection charges were higher in the MSSA group. Second, the
charges are assumed to be a result of MRSA or MSSA bacteremia. Hospital charges
unrelated to the bacteremia that were unequal between the groups could introduce bias
into the investigation and also inflate the difference in hospital charges between the
MRSA and MSSA and overestimate charge. There is no way to discern which charges
relate to the bacteremia from the aggregate total charge provided for this analysis.
However, controlling for severity of illness should help account for differences between
the MRSA and MSSA groups. It was assumed that all differences in post-infection
charge were attributed to the bacteremia. Given the study design, this limitation was
unavoidable.
Previous methods for calculating the economic burden of resistance have varied
largely. Many single center investigations were able to collect actual cost from their
institution.[12, 14, 15] Another investigation was able to identify only costs associated
with the SAB.[16] And one of these investigations was able to collect costs attributable
to SAB after hospital discharge.[16] Charges were not able to be sub-categorized in the
current study. Only an overall aggregate charge was available for each subject since the
data came from a large multi-hospital database.
The pilot investigation included transferred patients in the patient population.
However, transferred patients were excluded in this investigation. In both investigations
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there was no way to know the duration of hospitalization before the transfer. Including
these patients could lead to the inclusion of non-nosocomial infections. Excluding
transferred patients could underestimate the number of actual cases. Since the pilot
included only a tertiary care facility it was assumed that patients transferred there had
been at another facility previously. This investigation included all types of hospitals.
Therefore, it seemed more appropriate to exclude transferred patients. This means that
potential cases may have been excluded. The effects of excluding these patients were
thought to be minimal since only 55 MRSA and 19 MSSA patients were transferred from
another facility.
Three data manipulation steps led to the exclusion of potential patients. First,
several hospitals’ data were excluded when the Micro and Large datasets were merged.
This was most likely a result of hospitals subscribing to different Cerner services -- an
unavoidable circumstance that resulted in a smaller sample size. Cerner is a for-profit
company that provides information technology services to its clients. Each client
customizes the services it contracts for through Cerner which means that not all hospitals
manage the same data elements within their system. Second, only 2006 DRG codes were
used. This was done for consistency since all charges were inflated to their 2006 value.
Unfortunately, 122 observations were discarded. Almost all of them were surgical
DRGs. When DRGs are updated, their weights change. For the purposes of this project,
all the weights needed to be consistent. Third, patients with charges less than $11,896
and a LOS greater than nine days were excluded. It became obvious from looking at the
data that some observations were erroneous. Some charges were too low based on the
123

total LOS. The pilot investigation has a minimum charge of $11,896. Any observation
with a total charge lower than this was excluded. In the pilot investigation, the median
pre-infection LOS for MRSA was 10 days. A LOS greater that nine days should have a
total hospital charge greater than the minimum which was $11,896; therefore, any charge
less than $11,896 with a LOS greater than 9 days was excluded. This data manipulation
step excluded patients with extremely low charges and a long LOS.
Adjusting for underlying severity of illness was a major concern in this
investigation. There is currently no one well-validated, universally accepted illness
severity score for infectious disease outcomes.[27] One investigation did explore a
comorbidity risk-adjustment measure specifically for MRSA.[39] However, this measure
has not been widely used in the literature. Another investigation comparing two severity
of illness indices created for non-infectious disease related indications, the Charlson
comorbidity score and the Chronic Disease Score, found both to be indicators of
increased risk for a nosocomial infection based on preexisting comorbidities.[107] Other
investigations have used a variety of techniques including APACHE score [12, 18],
McCabe/Jackson score [11] and the Charlson comorbidity score.[60] The APACHE
score is intended for use with ICU patients while the McCabe/Jackson score has been
evaluated for non-ICU patients. DRGs have been used as a surrogate for severity of
underlying illness in MRSA bacteremia.[13] This approach was originally developed to
accurately assess the cost of hospitalization by adjusting for severity of illness within the
DRG classification scheme.[46, 47] This investigation used both DRG weights and the
Charlson comorbidity score to adjust for severity of underlying illness. However, it
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should be mentioned that the Charlson comorbidity score might not have been the ideal
method for controlling comorbid conditions. The adapted Charlson comorbidity score
uses ICD-9-CM information, which is based on discharge data. Therefore, additional
comorbidities that arose after the onset of infection would be intermediaries between
infection susceptibility and charge, thereby potentially biasing the study results.[107]
This investigation did not assess the appropriateness of a patient’s antibiotic
therapy. One previous investigation found that 32.9% of patients with a MRSA
bacteremia did not initially receive appropriate antibiotic therapy.[102] As previously
discussed, charges are higher for patients who have delayed initiation of appropriate
therapy.[108] Additionally, differences in antibiotics play a role in patient outcomes for
MRSA and MSSA infections.[109] For example, whether an antibiotic is bacteriostatic
or bacteriocidal could change the effectiveness and duration of treatment. Although
researchers are beginning to question the effectiveness of vancomycin for treating MRSA
bacteremia,[99] this investigation did not evaluate the efficacy of vancomycin.
Pharmacotherapy information was not included in the data provided by Cerner.
This investigation did not examine any patient clinical sub-populations in the
multivariable analysis. Staphylococcus aureus infections are a serious and frequent
complication of hemodialysis.[110] Two reports have been published specifically
evaluating the economic impact of SAB in end-stage renal disease patients undergoing
hemodialysis.[15, 16] This investigation deliberately did not focus on any particular
diagnosis sub-populations in an attempt to increase external validity.
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Finally, this study relied on previously collected data. Retrospective data can be
convenient since the researcher does not have to wait for the data to be prospectively
collected. However, records must be complete and accurate or the results could be
biased.[61] The final sample for this investigation was complete. However, many
potential observations were excluded from the sample because their data were not
complete. The advantage of the database used was the size. Even though many
observations were removed, the final sample was still large.

Future Research
Future research in this area should be focused on path analysis. Path analysis is
ideal for modeling an exposure, confounders, intermediaries and outcomes
simultaneously. This method is a suitable technique to tease out why MRSA infections
seem to cost more than MSSA infections. However, this technique requires much
forethought. The model is only as good as the a priori assumptions it is based on.
Developing a more complete path analysis model that includes all potential confounders
as well as post-infection LOS would be helpful. The model from this analysis suggests
the impact of susceptibility status on total charge was small. Creating a more
comprehensive path model would either support or refute this finding. Severity of illness
and mortality should be added to the model. This investigation should serve as a
baseline of comparison for future path analysis models.
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Conclusions
The broad purpose of this investigation was to explore the relationships between
susceptibility status (MRSA vs. MSSA), total hospital charge and LOS (pre- and postinfection). MRSA was associated with a $24,406 increase in total hospital charge. A
multivariable model took into account potential confounders and estimated a $22,889
adjusted increase. However, the multivariable indicated that the effect of infection
susceptibility was different based on the Charlson comorbidity score. For the majority of
patients, MRSA had higher total charges. But, as patients became more severely ill,
MRSA charges decreased while MSSA charges increased.
In the multivariable model with post-infection LOS as the outcome, the model
predicted a mean post-infection LOS increase of 1.3 days for MRSA over MSSA
patients. However, the magnitude of increased post-infection LOS based on pre-infection
LOS was different for MRSA and MSSA patients. For the majority of patients, there was
no difference in post-infection LOS based on susceptibility. But as pre-infection LOS
increased, post-infection LOS for MSSA patients became notably longer than MRSA
patients.
Path analysis incorporated all the variables of interest in one model.
Susceptibility status was not highly correlated with total charge or post-infection LOS.
This implies that susceptibility status may not highly influence charge or post-infection
LOS through the proposed model. However, two important confounders were not
included in the analysis (severity of illness and mortality). Future research should
incorporate these confounders in the structural equation models. The role of
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susceptibility status may still have an indirect effect on total charge or post-infection LOS
through confounders not included in this investigations path analysis.
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Appendix B
Codebook for Categorical Variables
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Variable Collected
Susceptibility
Gender
Admission Source

Variable Categories
& Subcategories
MRSA
MSSA
Gender

Variable Name

Variable Code

susceptibility

MRSA = 1
MSSA = 0
Male = 1
Female = 0
Referral =1

gender1

Referral
Physician referral
Clinic referral
HMO referral
Transfer
Transfer from a hospital
Transfer from a skilled nursing facility
(SNF)
Transfer from another health care
facility
Emergency Room
N/A
Not available
Null
Not mapped

admission_source

Transfer = 2

Emergency Room = 7
N/A = 3

(continued)
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Appendix B: (continued)
Variable
Collected
Status at
Discharge

Variable Categories
& Subcategories
Discharged Home
Discharged to home
Discharged/transferred to home under care of Home IV provider
Discharged/transferred to home with home health service

Variable Name

Variable Code

discharge

Discharged
Home = 1
Transferred =
2

Transferred
Discharged/transferred to another short term hospital
Discharged/transferred to SNF
Discharged/transferred to ICF
Discharged/transferred to another type of inpatient care institution
Discharged/transferred to another rehabilitation facility
Discharged/transferred to a long term care hospital
Hospice
Hospice / home
Hospice / medical facility
Expired
Other
Left AMA
Still patient or expected to return for outpatient services
Discharged/transferred within this institution to Medicare
approved swing bed
N/A
NULL
Not Mapped

Hospice = 6
Expired = 3
Other = 4

N/A = 5
(continued)

146

Appendix B: (continued)
Variable Collected
Discharge Status
Type of Payer

Variable Categories
& Subcategories
Discharged
Expired
N/A
Insured
BCBS
Other Commercial Payer
Other Government
Other Non-govt
Self-Insured
CHAMPUS (military dependents)
HMO/Managed care
Worker's Compensation
Medicare
Medicaid
Self Pay
N/A
Unknown/Missing/Invalid
Null
Not mapped
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Variable Name

Variable Code

mortality

Discharged = 1
Expired = 0
N/A=2
Insured = 1

payer

Medicare = 5
Medicaid = 4
Self Pay = 2
N/A = 5

Appendix C
Codebook for Continuous Variables

Variable Collected
Age
DRG weight
Charlson comorbidity score
Propensity score
Total hospital charge
Total length of stay
Pre-infection LOS
Post-infection LOS
DRG = diagnosis related group
LOS = length of stay

Unit of Measurement
year
n/a
n/a
n/a
dollars
day
day
day
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Variable Code
age
weights
charlson
prob
charge
total_LOS
pre_infection_LOS
post_infection_LOS

Appendix D
SAS Code
*Entire SAS code;
libname phd 'C:\Documents and Settings\Suzanne Phillips\Desktop\SAS PhD
files';
run;
libname phdfinal 'C:\Documents and Settings\Suzanne Phillips\My
Documents\PhD';
run;
*Micro data;
PROC IMPORT OUT= phd.phdmicro
DATAFILE= "C:\Documents and Settings\Suzanne
Phillips\Deskto
p\Suzanne_MRSA\all_criteria_ms_sep1.txt"
DBMS=DLM REPLACE;
DELIMITER='7C'x;
GETNAMES=YES;
DATAROW=2;
RUN;
ods html file = "phd.phdmicro";
libname phd 'C:\Documents and Settings\Suzanne Phillips\Desktop\SAS PhD
files';
proc print data=phd.phdmicro;
format id comma30.0;
run;
ods html close;
data phd.phdmicro1;
set phd.phdmicro;
format id comma31.0;
format SUSCEPTIBILITY comma3.0;
format microbial_code comma5.0;
run;
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*micro results with all observations;
proc freq data=phd.phdmicro1;
tables susceptibility;
run;
Proc sort data = phd.phdmicro1;
by id;
run;
proc freq data = phd.phdmicro1 noprint;
table id / out=phd.phdmicro1__1;
run;

*remove observations if susceptibility = 2,3,4,10,11;
data phd.phdmicro2;
set phd.phdmicro1;
if SUSCEPTIBILITY <7 then delete;
if SUSCEPTIBILITY > 9 then delete;
run;
proc sort data=phd.phdmicro2;
by id ascending susceptibility;
run;
proc sort data=phd.phdmicro2 out=phd.phdmicro_nodup
dupout=phd.phdmicrodups nodupkey;
by id;
run;
Proc sort data = phd.phdmicro_nodup;
by id;
run;
proc freq data = phd.phdmicro_nodup noprint;
table id / out=phd.phdmicronodup1__1;
run;

data phd.phdmicrodups (rename = (susceptibility = suscep));
set phd.phdmicrodups;
run;
*how to sort and merge.;
PROC SORT Data=phd.phdmicro_nodup;
BY id;
RUN;
PROC SORT Data=phd.phdmicrodups;
BY id;
RUN;
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DATA phd.phdmicroremerge;
MERGE phd.phdmicro_nodup phd.phdmicrodups;
BY id;
run;
*only 7 and 8 duplicates;
data phd.phdmicroremerge1;
set phd.phdmicroremerge;
if suscep = "." then delete;
run;
*no duplicates - final dataset;
data phd.phdmicrofinal;
set phd.phdmicroremerge;
if SUSCEPTIBILITY = 8 and suscep = 7 then delete;
if SUSCEPTIBILITY =7 and suscep = 8 then delete;
run;
*(micro masacure is complete);
Proc sort data = phd.phdmicrofinal;
by id;
run;
proc freq data = phd.phdmicrofinal noprint;
table id / out=phd.phdmicrofinal1__1;
run;
*Descriptive stats for just micro;
proc freq data=phd.phdmicrofinal;
tables susceptibility*microbial_code;
run;
proc freq data=phd.phdmicrofinal;
tables susceptibility;
run;
*large dataset;
PROC IMPORT OUT= phd.PHDlarge
DATAFILE= "C:\Documents and Settings\Suzanne
Phillips\Desktop\Suzanne_MRSA\emhdipipa_flag_icu_sep1.txt"
DBMS=DLM REPLACE;
DELIMITER='7C'x;
GETNAMES=YES;
DATAROW=2;
RUN;
data phd.phdlarge1;
set phd.phdlarge;
admit= INPUT(ADMITTED_DT_TM, DATE9.);
discharge= INPUT(DISCHARGED_DT_TM,DATE9.);
tolab= INPUT(MICRO_LAB_RECEIVED_DT_TM, DATE9.);
LOS_total= discharge- admit;
Pre_infection_LOS = tolab- admit;
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Post_infection_LOS = discharge- tolab;
Format admitdischargetolabdate9.;
format id comma32.;
run;
Proc sort data = phd.phdlarge1;
by id;
run;
proc freq data = phd.phdlarge1 noprint;
table id / out=phd.phdlarge1__1;
run;
* represents 6750 patients;
/* exclude if pre infection LOS < 2 days. */
data phd.phdlarge2;
set phd.phdlarge1;
if pre_infection_LOS >=2;
run;

Proc sort data = phd.phdlarge2;
by id;
run;
proc freq data = phd.phdlarge2 noprint;
table id / out=phd.phdlarge2__1;
run;
* this dataset has 3,313 obs;

*an aside, pre-infection LOS > 2 n=165,918 ;
data phd.phdlarge2_1;
set phd.phdlarge1;
if pre_infection_LOS < 2;
run;
proc sort data=phd.phdlarge2_2 out=phd.phdlarge2_4 noduprecs;
by id pre_infection_LOS;
run;
data phd.phdlarge2_4firstobs phd.dupobs2_4;
set phd.phdlarge2_4;
by id;
if first.id then output phd.phdlarge2_4firstobs;
else output phd.dupobs2_4;
run;
proc freq data= phd.phdlarge2_4firstobs;
tables ad_source;
run;
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/*After excluding these observations, n= 249,449*/
*phd.phdlarge3 has 249,449 obs;
/*Remove duplicate observations */
proc sort data=phd.phdlarge3 out=phd.phdlarge4 noduprecs;
by id pre_infection_LOS;
run;
*phd.phdlarge4 had 5799 obs but there are still some dup where multiple
cultures were taken in the same admission;
data phd.phdlargefirstobs phd.dupobs;
set phd.phdlarge4;
by id;
if first.id then output phd.phdlargefirstobs;
else output phd.dupobs;
run;
*phd.phdlargefirstobs has 3313 obs;
Proc sort data = phd.phdlargefirstobs;
by id;
run;
proc freq data = phd.phdlargefirstobs;
table id / out=phd.charlson_1;
run;

*Descriptive Statistics;
*large dataset hospitals by year;
data phd.phdlarge3_1;
set phd.phdlarge3;
format tolabyear4.;
run;
proc sort data=phd.phdlarge3_1 out=phd.phdlarge3_2;
by into_microlab_date;
run;
proc freq data=phd.phdlarge3_2;
tables hospital;
by into_microlab_date;
run;
*smaller dataset hospital by year;
data phd.phdlarge4_1;
set phd.phdlarge4;
format tolabyear4.;
run;
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proc sort data=phd.phdlarge4_1 out=phd.phdlarge4_2;
by into_microlab_date;
run;
proc freq data=phd.phdlarge4_2;
tables hospital;
by into_microlab_date;
run;
*final dataset;
data phd.phdlargefirstobs_1;
set phd.phdlargefirstobs;
format tolabyear4.;
run;
proc sort data=phd.phdlargefirstobs_1 out=phd.phdlargefirstobs_2;
by into_microlab_date;
run;
proc freq data=phd.phdlargefirstobs_2;
tables hospital;
by into_microlab_date;
run;
*merge micro and large file;
/*

micro data = phd.phdmicrofinal - 3275
descriptive data = phd.phdlargefirstobs - 3313
*/

PROC SORT Data=phd.phdmicrofinal;
BY id;
RUN;
PROC SORT Data=phD.phdlargefirstobs;
BY id;
RUN;
DATA phd.phd1;
MERGE phd.phdmicrofinal phD.phdlargefirstobs;
BY id;
run;
/* merged dataset (phd.phd1) contains 4855 obs */
data phd.phd2;
set phd.phd1;
if SUSCEPTIBILITY <7 then delete;
if SUSCEPTIBILITY > 9 then delete;
run;
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/* merged dataset (phd.phd2) missing micro data eliminated contains
3275 obs */
data phd.phd3;
set phd.phd2;
if Age <18 then delete;
run;
/* merged dataset (phd.phd3) contains 1733 obs */
*Calculate Charlson score;
data phd.charlson;
set phd.diagnosis_codes;
length uniqueid $ 35;
dx=icd9_diagnosis_code;
uniqueid = cat (encounterid);
run;
proc sort data=phd.charlson;
by encounterid;
run;
data a b c d e f g h i j k l m n o p q;
set phd.charlson;
if ((substr(dx,1,3) >= '531') & (substr(dx,1,3) <= '534')) then output
a;
if substr(dx,1,4) in ('2504','2505','2506','2507') then output b;
if ((substr(dx,1,3) >= '196') & (substr(dx,1,3) <= '199')) then output
c;
if substr(dx,1,3) in ('410','412') then output d;
if substr(dx,1,3) in ('428') or substr(dx,1,4) in
('4254','4255','4257','4258','4259') or substr(dx,1,5) in
('39891','40201','40211','40291','40401','40403','40411','40413','40491
','40493') then output e;
if substr(dx,1,3) in ('441','440') or substr(dx,1,4) in
('4439','V434','0930','4373','4431','4432','4438','4471','5571','5579')
then output f;
if substr(dx,1,3) in
('430','431','432','433','434','435','436','437','438') or
substr(dx,1,5)='36234' then output g;
if substr(dx,1,3)='290' or substr(dx,1,4) in ('2941','3312') then
output h;
if substr(dx,1,3) in
('490','491','492','493','494','495','496','500','501','502','503','504
','505') or substr(dx,1,4) in
('5064','4168','4169','5064','5081','5088') then output i;
if substr(dx,1,4) in
('4465','7100','7102','7103','7101','7104','7140','7141','7142','7148')
or substr(dx,1,3)='725' or substr(dx,1,5)='71481' then output j;
if substr(dx,1,4) in ('0706','0709','5733','5734','5738','5739','V427')
or substr(dx,1,5) in ('07022','07023','07032','07033','07044','07054')
or substr(dx,1,3) in ('570','571') then output k;
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if substr(dx,1,4) in ('2500','2501','2502','2503','2508','2509') then
output l;
if substr(dx,1,3) in ('342','343') or substr(dx,1,4) in
('3341','3440','3441','3442','3443','3444','3445','3446','3449') then
output m;
if substr(dx,1,3) in ('582','585','586','V56') or substr(dx,1,4) in
('5830','5831','5832','5834','5836','5837','5880','V420','V451') or
substr(dx,1,5) in
('40301','40311','40391','40402','40403','40412','40413','40492','40493
') then output n;
if substr(dx,1,3) in
('140','141','142','143','144','145','146','147','148','149','150','151
','152','153','154','155','156','157','158','159','160','161','162','16
3','164','165','166','167','168','169','170','171','172','174','175','1
76','177','178','179','180','181','182','183','184','185','186','187','
188','189','190','191','192','193','194','195','200','201','202','203',
'204','205','206','207','208') or substr(dx,1,4)='2386' then output o;
if substr(dx,1,4) in ('5722','5723','5724','5728','4560','4561','4562')
then output p;
if substr(dx,1,3) in ('042','043','044') then output q;
run;
proc freq data=a
table uniqueid /
proc freq data=b
table uniqueid /
proc freq data=c
table uniqueid /
run;
proc freq data=d
table uniqueid /
run;
proc freq data=e
table uniqueid /
run;
proc freq data=f
table uniqueid /
run;
proc freq data=g
table uniqueid /
run;
proc freq data=h
table uniqueid /
run;
proc freq data=i
table uniqueid /
run;
proc freq data=j
table uniqueid /
run;
proc freq data=k
table uniqueid /
run;

noprint;
out=afreq;
noprint;
out=bfreq;
noprint;
out=cfreq;
noprint;
out=dfreq;
noprint;
out=efreq;
noprint;
out=ffreq;
noprint;
out=gfreq;
noprint;
out=hfreq;
noprint;
out=ifreq;
noprint;
out=jfreq;
noprint;
out=kfreq;
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proc freq data=l
table uniqueid /
run;
proc freq data=m
table uniqueid /
run;
proc freq data=n
table uniqueid /
run;
proc freq data=o
table uniqueid /
run;
proc freq data=p
table uniqueid /
run;
proc freq data=q
table uniqueid /
run;

noprint;
out=lfreq;
noprint;
out=mfreq;
noprint;
out=nfreq;
noprint;
out=ofreq;
noprint;
out=pfreq;
noprint;
out=qfreq;

data phd.ulcer;
set afreq;
ulcer = 1;
drop count percent;
data phd.dmorgan;
set bfreq;
dmodamage = 2;
drop count percent;
data phd.mtumor;
set cfreq;
mtumor = 6;
drop count percent;
run;
data phd.myocard;
set dfreq;
myocard = 1;
drop count percent;
run;
data phd.chf;
set efreq;
chf = 1;
drop count percent;
run;
data phd.pvd;
set ffreq;
pvd = 1;
drop count percent;
run;
data phd.cerebro;
set gfreq;
cerebro = 1;
drop count percent;
run;
data phd.dementia;
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set hfreq;
dementia = 1;
drop count percent;
run;
data phd.copd;
set ifreq;
copd = 1;
drop count percent;
run;
data phd.rheum;
set jfreq;
rheum = 1;
drop count percent;
run;
data phd.mildliver;
set kfreq;
mildliver = 1;
drop count percent;
run;
data phd.dbnocomp;
set lfreq;
dbnocomp = 1;
drop count percent;
run;
data phd.hemiplegia;
set mfreq;
mtumor = 6;
drop count percent;
run;
data phd.renal;
set nfreq;
renal = 2;
drop count percent;
run;
data phd.cancer;
set ofreq;
cancer = 2;
drop count percent;
run;
data phd.msliver;
set pfreq;
msliver = 3;
drop count percent;
run;
data phd.hiv;
set qfreq;
hiv = 6;
drop count percent;
run;
data phd.phd3beforecharlson;
set phd.phd3;
length uniqueid $ 35;
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uniqueid = cat (id);
run;
proc sort data=phd.phd3beforecharlson;
by uniqueid;
run;

data phd.phd3_aftercharlson;;
merge phd.phd3beforecharlson phd.ulcer phd.dmorgan phd.mtumor
phd.myocard phd.chf phd.pvd phd.cerebro phd.dementia phd.copd phd.rheum
phd.mildliver phd.dbnocomp phd.hemiplegia phd.renal
phd.cancer phd.msliver phd.hiv;
by uniqueid;
if ulcer = . then ulcer = 0;
if dmodamage = . then dmodamage = 0;
if mtumor = . then mtumor = 0;
if myocard = . then myocard= 0;
if chf = . then chf=0;
if pvd = . then pvd=0;
if cerebro = . then cerebro=0;
if dementia = . then dementia = 0;
if copd = . then copd = 0;
if rheum = . then rheum = 0;
if dbnocomp = . then dbnocomp = 0;
if hemiplegia = . then hemiplegia = 0;
if renal = . then renal = 0;
if cancer = . then cancer = 0;
if msliver = . then msliver = 0;
if mildliver = . then mildliver = 0;
if hiv = . then hiv = 0;
charlson = sum(ulcer, dmodamage, mtumor, myocard, chf, pvd, cerebro,
dementia, copd, rheum, dbnocomp, hemiplegia, renal, cancer, msliver,
mildliver, hiv);
run;
data phd.mergedwithcharlson;
set phd.phd3_aftercharlson;
if id = . then delete;
run;

proc univariate data = phd.mergedwithcharlson;
class charlson;
var charlson;
run;

*add in DRG relative weights;
PROC IMPORT OUT= WORK.DRG
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DATAFILE= "C:\Documents and Settings\Suzanne Phillips\My
Doc
uments\PhD\2006drg_relative_weights.xls"
DBMS=EXCEL REPLACE;
SHEET="drgimport1$";
GETNAMES=YES;
MIXED=NO;
SCANTEXT=YES;
USEDATE=YES;
SCANTIME=YES;
RUN;
data phd.drg;
set drg;
run;
data phd.mergedwithcharlson1;
set phd.mergedwithcharlson;
if total_charges <=0 then delete;
drg = drg_id;
if drg <=0 then delete;
run;
*data set now contains 1088 obs;
*add drg weights (phd.drg) into dataset (phd.mergedwithcharlson);
PROC SORT Data= phd.drg;
BY drg;
RUN;
PROC SORT Data=phd.mergedwithcharlson1;
BY drg;
RUN;
DATA phd.drg_charlson;
MERGE phd.drg phd.mergedwithcharlson1;
BY drg;
run;
data phd.drg_charlson_1088;
set phd.drg_charlson_1088;
if id = . then delete;
run;
data phd.drg_charlson_drg_weight;
set phd.drg_charlson_1088;
if weights = . then delete;
if weights <= 0 then delete;
run;
*dataset contains 966 pts;
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*must adjust for inflation;
data phd.drg_charlson1;
set phd.drg_charlson_drg_weight;
discharge_year = year (discharge_date);
if discharge_year = 2000 then cpi=1.475;
if discharge_year = 2001 then cpi=1.384;
if discharge_year = 2002 then cpi=1.273;
if discharge_year = 2003 then cpi=1.186;
if discharge_year = 2004 then cpi=1.196;
if discharge_year = 2005 then cpi=1.064;
if discharge_year = 2006 then cpi=1;
charge = (total_charges * cpi);
run;
*re-visit LOS delete if pre-infection LOS is < 62 days;
data phd.drg_charlson2;
set phd.drg_charlson1;
if Pre_infection_LOS >62 then delete;
run;
*tweak the dataset - look for low cost payers;
data phd.drg_charlson3;
set phd.drg_charlson2;
if post_infection_los < 0 then delete;
run;
*sample size = 948 b/c 9 people has post-infection LOS < 0;
data phd.drg_charlson4;
set phd.drg_charlson3;
if charge < 11896 and LOS_total>= 9 then delete;
run;
*sample size = 930;
libname phdfinal 'C:\Documents and Settings\Suzanne Phillips\My
Documents\PhD';
run;
data phdfinal.final;
set phd.drg_charlson4;
run;
data phdfinal.final_1;
set phdfinal.final;
if ad_source = 1 then admission_source = 1;
if ad_source = 2 then admission_source = 1;
if ad_source = 3 then admission_source = 1;
if ad_source = 4 then admission_source = 2;
if ad_source = 5 then admission_source = 2;
if ad_source = 6 then admission_source = 2;
if ad_source = 10 then admission_source = 2;
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if
if
if
if
if
if

If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If
If

ad_source = 7 then admission_source = 7;
ad_source = 8 then admission_source = 8;
ad_source = 17 then admission_source = 3;
ad_source = 20 then admission_source = 3;
ad_source = 9 then admission_source = 3;
payer= 14 then payer = 1;
if payer= 15 then payer = 1;
if payer= 16 then payer = 1;
if payer= 18 then payer = 1;
if payer= 13 then payer = 1;
if payer= 21 then payer = 1;
if payer=1 then payer = 1;
if payer=2 then payer = 1;
if payer=4 then payer = 1;
if payer=17 then payer = 2;
if payer=22 then payer = 3;
if payer=20 then payer = 3;
if payer=23 then payer = 3;
if payer=10 then payer = 4;
if payer=11 then payer = 4;
if payer=6 then payer = 5;
if payer=7 then payer = 5;
DISCHARGE_CODE= 1 then discharge =1;
DISCHARGE_CODE= 8 then discharge =1;
DISCHARGE_CODE= 6 then discharge =1;
DISCHARGE_CODE= 2 then discharge =2;
DISCHARGE_CODE= 3 then discharge =2;
DISCHARGE_CODE= 4 then discharge =2;
DISCHARGE_CODE= 5 then discharge =2;
DISCHARGE_CODE= 22 then discharge =2;
DISCHARGE_CODE= 23 then discharge =2;
DISCHARGE_CODE= 11 then discharge =3;
DISCHARGE_CODE= 7 then discharge =4;
DISCHARGE_CODE= 12 then discharge =4;
DISCHARGE_CODE= 15 then discharge =4;
DISCHARGE_CODE= 18 then discharge =5;
DISCHARGE_CODE= 25 then discharge =5;
DISCHARGE_CODE= 13 then discharge =6;
DISCHARGE_CODE= 14 then discharge =6;
DISCHARGE_CODE= 1 then discharge_status =1;
DISCHARGE_CODE= 8 then discharge_status =1;
DISCHARGE_CODE= 6 then discharge_status =1;
DISCHARGE_CODE= 2 then discharge_status =1;
DISCHARGE_CODE= 3 then discharge_status =1;
DISCHARGE_CODE= 4 then discharge_status =1;
DISCHARGE_CODE= 23 then discharge_status =1;
DISCHARGE_CODE= 22 then discharge_status =1;
DISCHARGE_CODE= 5 then discharge_status =1;
DISCHARGE_CODE= 11 then discharge_status =0;
DISCHARGE_CODE= 7 then discharge_status =1;
DISCHARGE_CODE= 12 then discharge_status =1;
DISCHARGE_CODE= 15 then discharge_status =1;
DISCHARGE_CODE= 18 then discharge_status =2;
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If DISCHARGE_CODE= 25 then discharge_status =2;
If DISCHARGE_CODE= 13 then discharge_status =1;
If DISCHARGE_CODE= 14 then discharge_status =1;
If discharge_status =0 then mortality = 0;
If discharge_status =1 then mortality = 1;
run;
* Admission Source 1=referral, 2=transfer, 7=ER, 8=Court/Law
enforcement, 3=NA;
* Payer 1= Insured, 2=self pay, 3=N/A, 4=Medicaid, 5=Medicare;
*Discharge home=1, transfer = 2, expired =3, other = 4, N/A = 5,
Hospice = 6;
*Discharge status alive =1, dead = 0 n/a=2;

*categorical data frequency table;
proc freq data=phdfinal.final_1;
tables susceptibility * gender / chisq;
run;
proc freq data=phdfinal.final_1;
tables admission_source * susceptibility / chisq;
run;
proc freq data=phdfinal.final_1;
tables discharge * susceptibility
run;

/ chisq;

proc freq data=phdfinal.final_1;
tables discharge_status * susceptibility
run;
proc freq data=phdfinal.final_1;
tables payer * susceptibility / chisq;
run;
*continuous data analysis;
proc npar1way data=phdfinal.final_1 wilcoxon;
class susceptibility;
var age;
run;
proc npar1way data=phdfinal.final_1 wilcoxon;
class susceptibility;
var charlson;
run;
proc npar1way data=phdfinal.final_1;
class susceptibility;
var weights;
run;
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/ chisq;

proc npar1way data=phdfinal.final_1;
class susceptibility;
var pre_infection_LOS;
run;
proc npar1way data=phdfinal.final_1;
class susceptibility;
var post_infection_LOS;
run;
proc npar1way data=phdfinal.final_1;
class susceptibility;
var total_LOS;
run;
proc npar1way data=phdfinal.final_1;
class susceptibility;
var charge;
run;
*repeated measures ANOVA - interested in mean charge but must take into
account suseptibility status & hospital #;
Proc sort data = phdfinal.final_1;
by hospital susceptibility;
run;
proc transpose data=phdfinal.final_1
let
label = discharge_year
name = charge
out = phdfinal.final_1a;
by hospital susceptibility;
id discharge_year;
var charge;
run;
ODS graphics on;
proc glm data = phdfinal.final_1a;
class susceptibility hospital;
model _2000 _2001 _2002 _2003 _2004 _2005 _2006 = susceptibility
hospital;
repeated year 7 / printe summary;
run;
proc means data= phdfinal.final_1a;
by susceptibility;
var _2000 _2001 _2002 _2003 _2004 _2005 _2006;
run;
proc plot data = phdfinal.final_1;
by descending susceptibility;
plot charge*discharge_year;
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run;
Proc sort data = phdfinal.final_1;
by discharge_year susceptibility;
run;
proc gplot data= phdfinal.final_1;
PLOT charge*discharge_year=susceptibility ;
RUN;
symbol1 v=triangle c = r;
proc boxplot data=phdfinal.final_1;
plot charge*discharge_year /
boxstyle=schematic
vaxis=axis2
cboxes
= bl
clipfactor = 2;
insetgroup nhigh mean/ header = 'Outliers per year';
label charge='Total Charge in dollars';
label discharge_year='Discharge Year';
run;

*propensity score - hospital size, hospital teaching status,
urban/rural status;
data phdfinal.final_1a;
set phdfinal.final_1;
if susceptibility = 7 then susceptibility = 1;
if susceptibility = 8 then susceptibility = 0;
run;

proc logistic data = phdfinal.final_1a descending;
class bedteach urban_rural_status_ind;
model susceptibility = bed teach urban_rural/ lackfit corrb;
OUTPUT OUT= phdfinal.final_2 prob=prob;
RUN;

proc univariate data=phdfinal.final_2 plot;
var prob;
run;
Proc sort data = phdfinal.final_2;
by susceptibility;
run;
symbol1 v=triangle c = r;
proc boxplot data=phdfinal.final_2;
plot prob*susceptibility /
boxstyle=skeletal
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vaxis=axis2
cboxes
= bl;
label prob ='Propensity Score';
label susceptibility ='Susceptibility';
run;
proc rank data=phdfinal.final_2 groups = 5 out = phdfinal.rank;
ranks ranks;
var prob;
run;
data phdfinal.final_2a;
set phdfinal.rank;
quintile = ranks + 1;
if quintile = 2 then ps2
if quintile = 3 then ps3
if quintile = 4 then ps4
if quintile = 5 then ps5
run;

=1;
=1;
=1;
=1;

else
else
else
else

ps2
ps3
ps4
ps5

=
=
=
=

0;
0;
0;
0;

proc freq data=phdfinal.final_2a;
tables quintile*susceptibility;
run;
proc univariate data=phdfinal.final_2a plot;
var prob quintile;
run;
*propensity score = prob;
*Univariate analysis (obj 2)each variable by charge;
proc genmod data = phdfinal.final_2a;
model charge = susceptibility age / dist=gamma link=log obstats;
run;
proc genmod data = phdfinal.final_2a;
model charge = susceptibility weights / dist=gamma link=log
obstats;
run;
proc genmod data = phdfinal.final_2a;
model charge = susceptibility charlson / dist=gamma link=log
obstats;
run;
proc genmod data = phdfinal.final_2a;
model charge = susceptibility pre_infection_LOS / dist=gamma
link=log obstats;
run;
proc genmod data = phdfinal.final_2a;
model charge = susceptibility mortality / dist=gamma link=log
obstats;
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run;
proc genmod data = phdfinal.final_2a;
class gender;
model charge = susceptibility gender / dist=gamma link=log
obstats;
run;

*multivarable model - obj 2;
proc genmod data = phdfinal.final_2a;
class gender;
model charge = susceptibility gender prob weights charlson age
pre_infection_LOS mortality / dist=gamma link=log obstats;
run;
*remove age;
proc genmod data = phdfinal.final_2;
class gender;
model charge = susceptibility gender prob weights charlson
pre_infection_LOS mortality / dist=gamma link=log obstats;
run;
*test homogeneity of slope assumption;
data phdfinal.final_3;
set phdfinal.final_2a;
if GENDER = 'Female' then sex = '0';
Else sex = '1';
gender1=input(sex,comma4.);
X3 = susceptibility * gender1;
x2 = susceptibility * weights;
x1 = susceptibility * charlson;
x4 = susceptibility * pre_infection_LOS;
x5 = susceptibility * mortality;
X6 = weights*pre_infection_LOS;
X7 = gender1 * charlson;
X8 = weights * charlson;
X9 = weights*mortality;
X10 = weights* gender1;
X11 = gender1 * mortality;
X12 = gender1 * pre_infection_LOS;
X13 = charlson * pre_infection_LOS;
X14 = charlson*mortality;
X15 = pre_infection_LOS * mortality;
run;

proc genmod data = phdfinal.final_3;
class gender;
model charge = susceptibility gender prob weights charlson
pre_infection_LOS mortality x1 x2 x3 x4 x5
/ dist=gamma link=log type1;
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run;

*2-way interactions;
proc genmod data = phdfinal.final_3;
model charge = susceptibility gender1 prob weights charlson
pre_infection_LOS mortality x1 x2 x6 x7 x8 x9
x10 x11 x12 x13 x14 x15/ dist=gamma link=log type1;
run;
*final model obj 2;
data phdfinal.final_3a;
set phdfinal.final_3;
if susceptibility = 7 then susceptibility = 1;
if susceptibility = 8 then susceptibility = 0;
run;
proc genmod data = phdfinal.final_3a;
model charge = susceptibility gender1 prob weights charlson
pre_infection_LOS mortality x1 x2 x6 x7
/ dist=gamma link=log covb corrb obstats type1 type3 waldci;
output out=phdfinal.gencook resraw=resraw reschi=reschi
stdreschi=stdreschi pred=pred resdev=resdev;
run;
proc univariate data = phdfinal.gencook;
var pred;
run;
proc sort data = phdfinal.gencook;
by susceptibility;
run;
proc univariate data = phdfinal.gencook;
by susceptibility;
var pred;
run;
*reschi are pearson residuals;
proc
plot
plot
plot
plot
plot
run;

plot data=phdfinal.gencook;
charge*pred;
stdreschi * pred;
resraw * pred;
reschi * pred;
resdev * pred;

*influential diagnostics ;
ods output covb=covb parameterestimates=parameterestimates;
proc genmod data=phdfinal.final_3;
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model charge = susceptibility gender1 prob weights charlson
pre_infection_LOS mortality x1 x2 x6 x7
/ dist=gamma link=log r covb corrb obstats type1 type3 waldci;
output out=phdfinal.gencook2 resraw=resraw reschi=reschi
stdreschi=stdreschi pred=pred;
run;
proc iml;
use phdfinal.gencook2;
read all var {susceptibility gender1 prob weights charlson
pre_infection_LOS mortality x1 x2 x6 x7} into x;
read all var {charge} into y;
read all var {resraw} into resraw;
read all var {reschi} into reschi;
read all var {stdreschi} into stdreschi;
use covb;
read all var {prm1 prm2 prm3 prm4 prm5 prm6 prm7 prm8 prm9 prm10 prm11
prm12 scale} into covb;
use parameterestimates;
read all var {estimate} into estimate;
p=ncol(x);
n=nrow(x);
/*scale = estimate[p+1.]##2;*/
scale = estimate[p+2.]##2;
rr=(reschi/stdreschi)##2;
invrr = 1/rr;
stddev=sqrt(vecdiag(covb));
add=j(n,1,1);
newx=add||x||add;
/*tx = t(x);*/
tx = t(newx);
lev = J(n,1.1)- rr/scale;
D=(1/p)#(lev/(1-lev))#(stdreschi##2);
dfbeta = covb * tx * diag(invRR#resraw);
dfbetas = dfbeta#(stddev##-1);
print
print
print
print
run;

lev;
D;
dfbeta;
dfbetas;

proc univariate data=phdfinal.gencook2;
var pred;
run;
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proc univariate data=phdfinal.gencook2;
by susceptibility;
var pred;
run;

*removed if dev residuals > 3 - 5 obs were deleted (n=925);
data phdfinal.gencook2a;
set phdfinal.gencook;
if resdev > 3 then delete;
run;
*rerun analysis;
proc genmod data = phdfinal.gencook2a;
model charge = susceptibility age / dist=gamma link=log obstats;
run;
proc genmod data = phdfinal.gencook2a;
model charge = susceptibility weights / dist=gamma link=log
obstats;
run;
proc genmod data = phdfinal.gencook2a;
model charge = susceptibility charlson / dist=gamma link=log
obstats;
run;
proc genmod data = phdfinal.gencook2a;
model charge = susceptibility pre_infection_LOS / dist=gamma
link=log obstats;
run;
proc genmod data = phdfinal.gencook2a;
model charge = susceptibility mortality / dist=gamma link=log
obstats;
run;
proc genmod data = phdfinal.gencook2a;
class gender;
model charge = susceptibility gender / dist=gamma link=log
obstats;
run;

*rerun multivarable model - obj 2;
proc genmod data = phdfinal.gencook2a;
model charge = susceptibility prob weights charlson
pre_infection_LOS mortality / dist=gamma link=log obstats;
run;
*test homogeneity of slope assumption;
data phdfinal.gencook2aa;

170

set phdfinal.gencook2a;
x2 = susceptibility * weights;
x1 = susceptibility * charlson;
x4 = susceptibility * pre_infection_LOS;
x5 = susceptibility * mortality;
X6 = weights*pre_infection_LOS;
X8 = weights * charlson;
X9 = weights*mortality;
X10 = weights* gender1;
X13 = charlson * pre_infection_LOS;
X14 = charlson*mortality;
X15 = pre_infection_LOS * mortality;
run;
proc genmod data = phdfinal.gencook2aa;
class gender;
model charge = susceptibility gender prob weights charlson
pre_infection_LOS mortality x1 x2 x4 x5
/ dist=gamma link=log type1;
run;

*2-way interactions;
proc genmod data = phdfinal.gencook2aa;
model charge = susceptibility gender1 prob weights charlson
pre_infection_LOS mortality x1 x6 x8 x9
x10 x13 x14 x15/ dist=gamma link=log type1;
run;
*keep only x1 and x6;
*final model obj 2;
data phdfinal.gencook2aaa;
set phdfinal.gencook2aa;
if susceptibility = 7 then susceptibility = 1;
if susceptibility = 8 then susceptibility = 0;
run;
proc genmod data = phdfinal.gencook2aaa;
model charge = susceptibility prob weights charlson
pre_infection_LOS mortality x1 x6
/ dist=gamma link=log covb corrb obstats type1 type3 waldci;
output out=phdfinal.gencook resraw=resraw reschi=reschi
stdreschi=stdreschi pred=pred resdev=resdev;
run;
proc univariate data = phdfinal.gencook2aaa;
var pred;
run;
proc sort data = phdfinal.gencook2aaa;;
by susceptibility;
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run;
proc univariate data = phdfinal.gencook2aaa;
by susceptibility;
var pred;
run;
*rerun analysis with propensity scores as quintiles;
proc genmod data = phdfinal.gencook2aaa;
model charge = susceptibility ps2 ps3 ps4 ps5 weights charlson
pre_infection_LOS mortality x1 x6
/ dist=gamma link=log covb corrb obstats type1 type3 waldci;
output out=phdfinal.gencook1 resraw=resraw reschi=reschi
stdreschi=stdreschi pred=pred resdev=resdev;
run;

*Univariate analysis (obj 3)each variable by post-infection LOS;
*propensity score = prob;
*Univariate analysis (obj 3)each variable by charge;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility age / dist=gamma
link=log obstats;
run;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility weights / dist=gamma
link=log obstats;
run;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility charlson / dist=gamma
link=log obstats;
run;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility pre_infection_LOS /
dist=gamma link=log obstats;
run;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility mortality / dist=gamma
link=log obstats;
run;
proc genmod data = phdfinal.gencook2aaa;
class gender;
model post_infection_LOS = susceptibility gender / dist=gamma
link=log obstats;
run;
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*multivarable model - obj 3;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility prob weights charlson
age pre_infection_LOS mortality / dist=gamma link=log obstats;
run;
*remove age;
proc genmod data = phdfinal.gencook2aaa;
model post_infection_LOS = susceptibility prob weights
charlson pre_infection_LOS mortality / dist=gamma link=log obstats;
run;
*test homogeneity of slope assumption;
data phdfinal.gencook2aaaa;
set phdfinal.gencook2aaa;
x2 = susceptibility * weights;
x1 = susceptibility * charlson;
x4 = susceptibility * pre_infection_LOS;
x5 = susceptibility * mortality;
X6 = weights*pre_infection_LOS;
X8 = weights * charlson;
X9 = weights*mortality;
X13 = charlson * pre_infection_LOS;
X14 = charlson*mortality;
X15 = pre_infection_LOS * mortality;
run;
proc genmod data = phdfinal.gencook2aaaa;
model post_infection_LOS = susceptibility prob weights charlson
pre_infection_LOS mortality x4 x2 x1 x5
/ dist=gamma link=log type1;
run;

*2-way interactions;
proc genmod data = phdfinal.gencook2aaaa;
model post_infection_LOS = susceptibility prob weights charlson
pre_infection_LOS mortality x4 x13 x9
x14 x8 x15/ dist=gamma link=log type1;
run;
*final model obj 3;
proc genmod data = phdfinal.gencook2aaaa;
model post_infection_LOS = susceptibility prob weights charlson
pre_infection_LOS mortality x4 x13
/ dist=gamma link=log covb corrb obstats type1 type3 waldci;
output out=phdfinal.LOSgencookaa resraw=resraw reschi=reschi
stdreschi=stdreschi pred=pred resdev=resdev;
run;
proc univariate data = phdfinal.LOSgencookaa;
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var pred2;
run;
proc sort data = phdfinal.LOSgencook;
by susceptibility;
run;
proc univariate data = phdfinal.LOSgencook;
by susceptibility;
var pred2;
run;

*path analysis;
proc calis data=phdfinal.gencook2aaaac corr residual pall toteff;
var susceptibility pre_infection_LOS Post_infection_LOS charge;
lineqs
Post_infection_LOS = b32 pre_infection_LOS + b31 susceptibility + e3,
charge = b43 Post_infection_LOS + b42 pre_infection_LOS + e4;
std
susceptibility = var_susc,
pre_infection_LOS = var_preLOS,
e3 = var_e3,
e4 = var_e4;
cov
susceptibility pre_infection_LOS = c_spre;
run;
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